1
|
D'Oronzo S, Cives M, Lauricella E, Stucci S, Centonza A, Gentile M, Ostuni C, Porta C. Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience. Clin Exp Med 2024; 24:7. [PMID: 38240866 PMCID: PMC10798926 DOI: 10.1007/s10238-023-01280-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Accepted: 11/18/2023] [Indexed: 01/22/2024]
Abstract
Bone metastases (BM) are a serious cancer complication, potentially causing substantial morbidity. Among the clinical issues related to BM, there is the lack of specific tools for early diagnosis and prognosis. We explored whether combining bone turnover markers (BTM) with dual-energy X-ray absorptiometry (DXA) assessment could identify early BM progression and risk of skeletal-related events (SREs) during zoledronate treatment. Before the initiation of zoledronate (T0) and after six months of treatment (T1), serum levels of five BTM were measured, and patients (N = 47) underwent DXA evaluation. Standard radiological imaging was performed to assess bone tumor response to medical anti-cancer treatment. High tumor burden in bone correlated with higher serum CTX (p = 0.007) and NTX (p = 0.005) at baseline. Low concentrations of OPG at T0 predicted BM progression with a sensitivity and specificity of 63% and 77%, respectively, when a cutoff of 5.2 pmol/l was used; such a predictive meaning was stronger in patients with lytic BM (sensitivity: 88%, specificity: 80%; p = 0.0006). As for the risk of SREs, we observed an association between low baseline OC (p = 0.04) and OPG (p = 0.08) and the onset of any-time SREs, whereas an increase in OPG over time was associated with reduced risk of on-study events (p = 0.03). Moreover, a statistically significant correlation emerged between low baseline lumbar T-score and femur BMD and on-study SREs (p < 0.001 in both instances). These findings suggest that addition of DXA to BTM dosage could help stratifying the risk of SREs at the time of BM diagnosis but does not enhance our capability of detecting bone progression, during zoledronate treatment.
Collapse
Affiliation(s)
- Stella D'Oronzo
- Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Bari, Italy.
- Division of Medical Oncology, A.O.U. Consorziale Policlinico Di Bari, Bari, Italy.
| | - Mauro Cives
- Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Bari, Italy
- Division of Medical Oncology, A.O.U. Consorziale Policlinico Di Bari, Bari, Italy
| | - Eleonora Lauricella
- Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Bari, Italy
| | - Stefania Stucci
- Division of Medical Oncology, A.O.U. Consorziale Policlinico Di Bari, Bari, Italy
| | - Antonella Centonza
- Unit of Oncology, Fondazione IRCCS "Casa Sollievo Della Sofferenza", San Giovanni Rotondo, Italy
| | - Marica Gentile
- Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Bari, Italy
| | - Carmela Ostuni
- Oncology Unit of National Institute of Gastroenterology - IRCCS "Saverio de Bellis", Research Hospital Castellana Grotte, Bari, Italy
| | - Camillo Porta
- Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Bari, Italy
- Division of Medical Oncology, A.O.U. Consorziale Policlinico Di Bari, Bari, Italy
| |
Collapse
|
2
|
De Luca A, Flammini G, Vittorini P, Muselli M, Mastrantonio R, Cipollone C, Gentile M, Petti A, D'Innocenzo M, Fabiani L. Impact of the healthcare reorganization of the Local Health Authority services in Rieti (Italy) during the SARS-CoV-2 pandemic. Ann Ig 2023; 35:441-453. [PMID: 36795478 DOI: 10.7416/ai.2023.2560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
Background The need to contain the spread of the SARS-CoV-2 pandemic has forced national and local organizations to define and implement targeted emergency response and management measures. As the knowledge about the infection grew, a wider range of organizational measures were deployed. Methods This study involves the SARS-CoV-2 infected people managed by the Local Health Authority of Rieti (Italy). Diagnostic test waiting times and hospital admission rates in the Province of Rieti are investigated as the pandemic evolved. Trends were analyzed in relation to the tempora spreading of SARS-CoV-2, to the organizational actions taken by the Local Health Authority of Rieti, and to the deployment of actions across the territory. A municipalities classification of the province of Rieti was conducted after a cluster analysis based on the diagnostic test waiting times and the hospital admission rates. Results Our findings show a declining trend, thus indicating a possible positive effect of the measures taken to contain the pandemic. The cluster analysis of the municipalities of the Province of Rieti makes evident an inhomogeneous geographical distribution of examined parameters (diagnostic test waiting times and the hospital admission rates), demonstrating the capability of Local Health Authority of Rieti to reach even the most disadvantaged areas and implying that the differences are due to the demographical variabilities. Conclusion Despite some limitations, this study outlines the importance of management measures in response of the pandemic. These measures should adapt to social, cultural and geographical nature of the territory involved. The findings of the present study will contribute to the update of further pandemic preparedness plans of the Local Health Authorities.
Collapse
Affiliation(s)
- A De Luca
- Local Health Authority of Rieti, Italy
| | - G Flammini
- Department of Life, Health & Environmental Sciences, University of L'Aquila, Italy
| | - P Vittorini
- Local Health Authority of Avezzano-Sulmona-L'Aquila, Italy
| | - M Muselli
- Department of Life, Health & Environmental Sciences, University of L'Aquila, Italy
| | - R Mastrantonio
- Department of Life, Health & Environmental Sciences, University of L'Aquila, Italy
| | - C Cipollone
- Local Health Authority of Avezzano-Sulmona-L'Aquila, Italy
| | - M Gentile
- Local Health Authority of Rieti, Italy
| | - A Petti
- Local Health Authority of Rieti, Italy
| | | | - L Fabiani
- Department of Life, Health & Environmental Sciences, University of L'Aquila, Italy
| |
Collapse
|
3
|
Tronconi F, Nero C, Giudice E, Salutari V, Musacchio L, Ricci C, Carbone MV, Ghizzoni V, Perri MT, Camarda F, Gentile M, Berardi R, Scambia G, Lorusso D. Advanced and recurrent endometrial cancer: State of the art and future perspectives. Crit Rev Oncol Hematol 2022; 180:103851. [DOI: 10.1016/j.critrevonc.2022.103851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2022] [Revised: 09/02/2022] [Accepted: 10/12/2022] [Indexed: 11/06/2022] Open
|
4
|
Musacchio L, Cicala CM, Camarda F, Ghizzoni V, Giudice E, Carbone MV, Ricci C, Perri MT, Tronconi F, Gentile M, Salutari V, Scambia G, Lorusso D. Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? ESMO Open 2022; 7:100536. [PMID: 35849879 PMCID: PMC9294238 DOI: 10.1016/j.esmoop.2022.100536] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Revised: 05/17/2022] [Accepted: 06/14/2022] [Indexed: 12/21/2022] Open
Abstract
Immune checkpoint inhibitors (ICIs) have completely reshaped the treatment of many malignancies, with remarkable improvements in survival outcomes. In ovarian cancer (OC), however, this emerging class of drugs has not yet found a favorable use due to results from phase I and II studies, which have not suggested a substantial antitumoral activity of these agents when administered as monotherapy. Robust preclinical data seem to suggest that the combination ICIs with poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) may result in a synergistic activity; furthermore, data from phase II clinical studies, evaluating this combination, have shown encouraging outcomes especially for those OC patients not suitable for platinum retreatment. While waiting for ongoing phase III clinical trial results, which will clarify the role of ICIs in combination with PARPis in the newly diagnosed OC, this review aims to summarize the preclinical data and clinical evidence available to date. Preclinical data indicate that PARPis exhibit immune modulating properties. The combination of PARPi with ICIs displays significant synergistic activity in preclinical models. Phase I and II clinical trials showed encouraging results for this combination, especially in platinum-resistant OC. Four ongoing phase III trials exploring the combination in first-line setting will delineate the role of immunotherapy in OC.
Collapse
Affiliation(s)
- L Musacchio
- Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. https://twitter.com/lucia_musacchio
| | - C M Cicala
- Department of Medical and Surgical Science, Medical Oncology Unit, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. https://twitter.com/carlomcicala
| | - F Camarda
- Department of Medical and Surgical Science, Medical Oncology Unit, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. https://twitter.com/florianacamarda
| | - V Ghizzoni
- Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
| | - E Giudice
- Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
| | - M V Carbone
- Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
| | - C Ricci
- Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
| | - M T Perri
- Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
| | - F Tronconi
- Medical Oncology Unit, Marche Polytechnic University, Ancona, Italy
| | - M Gentile
- Department of Biomedical Sciences and Human Oncology, University of Bari, Bari, Italy
| | - V Salutari
- Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
| | - G Scambia
- Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Department of Life Science and Public Health, Catholic University of Sacred Heart Largo Agostino Gemelli, Rome, Italy
| | - D Lorusso
- Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Department of Life Science and Public Health, Catholic University of Sacred Heart Largo Agostino Gemelli, Rome, Italy.
| |
Collapse
|
5
|
Piomboni P, Luongo F, Dragoni F, Gentile M, Boccuto A, Boschi L, Morgante G, Vicenti I, Zazzi M, Luddi A. P-460 SARS-CoV-2 infection of human ovarian cells: an in vitro model for the detection of the virus entry into the host cells. Hum Reprod 2022. [PMCID: PMC9384335 DOI: 10.1093/humrep/deac107.432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Study question Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can enter and actively infect human follicular and granulosa cells? Summary answer Follicular Granulosa (GCs) and Cumulus cells (CCs) are susceptible to SARS-CoV-2 infection that is able to reproduce. What is known already To enter host cells, SARS-CoV-2 uses Spike S1 subunit to bind the receptor angiotensin-converting enzyme2 (ACE2), S2 subunit is cleaved by the host transmembrane serine protease 2 (TMPRSS2) or by cathepsin L (CSTL) to produce unlocked, fusion-catalyzing viral forms. CD147 (BSG) has been proposed as an additional host receptor for SARS-CoV-2. Female fertility is strictly dependent on oocyte quality and competence. ACE2 is highly expressed in the human ovaries and in the stromal endometrial cells, as well as in GCs and oocytes. The expression of ACE2 strongly suggests that it is potentially at a high risk of SARS-CoV-2 infection. Study design, size, duration In order to analyze the presence of host receptors ACE2 and co-receptors TMPRSS2-CSTL and BSG and consequently the susceptibility of GCs and CCs to SARS-CoV2 infection. GCs and CCs were collected from about 25 patients undergoing IVF/ICSI cycles at the UOSA of Assisted Reproductive techniques, from March 2020 to October 2021 at the Center of Couple Sterility, Siena University Hospital. Participants/materials, setting, methods GCs and CCs were collected from women undergoing IVF cycle. GCs were recovered from the follicular fluid according to the procedure previously published. After oocyte denuding, CCs were isolated and both GCs and CCs co-cultured with SARS-CoV-2 then the supernatant was used to infect VERO6 Cells. Host factors and SARS-CoV2 expression/localization were confirmed by RT-PCR, Western blot and Immunofluorescence. SARS-CoV2 infection and its effect on GCs and CCs were evaluated by Transmission and Immuno-electron microscopy. Main results and the role of chance qRT-PCR analysis and WB showed that ACE2, TMPRSS2, BSG and CTSL transcripts were expressed in both GCs and CCs cells, even if at different levels. ACE2 transcript was significantly increased in the CCs (0.43 vs 0.15; p < 0.05) with respect to GCs; this datum is very interesting since CCs are the follicular cells able to establish intimate connections with the developing oocyte (e.g. gap junctions). Therefore, contrary to what can be assumed, human CCs cannot act as a barrier against virus entry into the oocyte. Coreceptor BSG and CTSL were the most expressed in GCs with respect to TMPRSS2, (0.7 vs 0.3 and 0.8 vs 0.4 respectively; p < 0.05). Ultrastructural evaluation of human GCs and CCs infected with SARS-CoV-2 was carried out at different time points post-infection (24h, 48h and 72h). Infected human GCs showed cell-associated virus-like particles, virions were approximately spherical, with a diameter outside the lipid bilayer ranging from 50-150 nm and ultrastructural characteristics consistent with those described for other coronaviruses. Complete virions were also observed inside the cytoplasm as single or small groups of particles, either dispersed or within large vesicles. Immunoelectron microscopy confirmed these particles as SARS-CoV2. Limitations, reasons for caution This is a human in vitro study, and we cannot predict all the implications in female fertility and related to the oocyte Wider implications of the findings We provide evidence in favor of SARS-CoV-2 infection in GCs and CCs, the ovarian somatic cells that support oocyte development and competence acquisition. The close relationship between oocytes and follicular cells raises the hypothesis that these cells may represent a vehicle for the oocyte SARS-CoV-2 infection Trial registration number Not applicable
Collapse
Affiliation(s)
- P Piomboni
- University of Siena, Molecular and Developmental Medicine , Siena, Italy
| | - F.P Luongo
- University of Siena, Molecular and Developmental Medicine , Siena, Italy
| | - F Dragoni
- University of Siena, Department of Medical Biotechnologies , Siena, Italy
| | - M Gentile
- University of Siena, Department of Life Sciences , Siena, Italy
| | - A Boccuto
- University of Siena, Department of Medical Biotechnologies , Siena, Italy
| | - L Boschi
- University of Siena, Molecular and Developmental Medicine , Siena, Italy
| | - G Morgante
- University of Siena, Molecular and Developmental Medicine , Siena, Italy
| | - I Vicenti
- University of Siena, Department of Medical Biotechnologies , Siena, Italy
| | - M Zazzi
- University of Siena, Department of Medical Biotechnologies , Siena, Italy
| | - A Luddi
- University of Siena, Molecular and Developmental Medicine , Siena, Italy
| |
Collapse
|
6
|
Montano L, Gentile R, Gentile M, Gentile T, Spinelli M, Carolina F, Notari T, Piscopo M, Amoresano A, Raimondo S. P-411 Blood concentrations of specific (PCBs) congeners and abortion rates in healthy women undergoing IVF cycles living in areas with high and low pollution. (EcoFoodFertility Project). Hum Reprod 2022. [DOI: 10.1093/humrep/deac107.388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Study question
Human exposure to polychlorinated biphenyls (PCBs) exists despite its ceased production since 1977. PCBs congeners harm reproductive health, but data remain inconclusive.
Summary answer
Evaluate relationship between blood concentrations of specific (PCBs) congeners and abortion rates in women undergoing IVF cycles living in areas with high and low pollution.
What is known already
PCBs are a class of synthetic chemicals that were widely used in industry until the 1970s and are found in many consumer products as refrigerants in electrical equipment, as flame retardants in plastics production and electronics. Continuous exposure to PCBs is of concern because they fall into the group of endocrine disruptors (EDCs), PCB congeners can spread throughout the female reproductive tract. Indeed, they have been found in human follicle fluids, placenta, amniotic fluid in embryos and fetuses Despite multiple reproductive health effects in women was reported, the results are sometimes inconsistent between experimental and epidemiological studies.
Study design, size, duration
In the frame of EcoFoodFertility Project, a cross sectional study conducted in Campania Region (Italy) to assess environmental impact on fertility and human health, blood samples were collected during the IVF cycles of the 65 women (aged 27.8 + 3.6) no smokers, BMI 23.5 – 27.9, normal menstruation, in two areas with high and low pollution between 2017 and 2019. The PCBs congeners we investigated were: estrogenic congeners (31,44,52,101,153), anti-estrogenic congeners (77,105,110,114,126,156,169) and other (28,118,138,180).
Participants/materials, setting, methods
Group A (n = 30) living in low polluted area (LPA), alto Medio Sele in province of Salerno, and group B (n = 35) living in highly polluted area (HPA), known as the “Land of Fires” due to the many sources of pollution. The blood sample was taken on the day of the oocyte pick-up and PCBs were measured by Gas Chromatography Coupled to (tandem) Mass Spectrometry. Statistical analyses were performed by GraphPad Prism 9.
Main results and the role of chance
Blood concentrations of PCBs are expressed as wet weight (nanograms per gram of serum) and as standardised lipid concentrations (nanograms per gram lipid). The PCB 169 congener was found in the highest concentration, 229.62 ng/g and, on average, accounted for 46.2 % of ΣPCBs tested. The PCB 77 (p < 0.05) and 118 ((p < 0.001) congeners were significantly higher in participants permanently living in HPA (Group B). For the other congeners, no significant variation was found. No significant variations between the two groups for oocyte pick-up rate, metaphase I and II oocyte ratio was found, fertilisation rate and pregnancy rate. Furthermore, the probability of embryo implantation was similar between the two groups, but the abortion rate was 3.0 times higher in group B. The probability of live births is 85.7% in group A and 53.85% in group B.These findings, even if the results between PCBs exposure and reproductive outcomes are due to the different congeners of these chemical compounds and unknown confounding factors and exposure times may be implicated, however suggest an association between the detection of specific PCB congeners and increased abortion rates in women undergoing IVF cycles that cannot be understimated.
Limitations, reasons for caution
Although we have set up a strict control and survey protocol, our study also has limitations due to the relatively small sample size of the groups and as with almost all epidemiological studies on environmental impact, there may be confounders or co-exposures that could interfere with the observed associations.
Wider implications of the findings
Although PCBs are no longer produced, the exposure remains widespread due to their long biological half-life, accumulation in the food chain and human health impacts are still reported. Our findings confirm these concerns, therefore, the study of these old chemicals is still relevant and important and should be expanded.
Trial registration number
not applicable
Collapse
Affiliation(s)
- L Montano
- Andrology Unit and Service of Lifestyle Medicine in UroAndrology- Local Health Authority ASL Salerno- Coordination Unit of the network for Environmental and Reproductive Health EcoFoodFertility research project- “Oliveto Citra Hospital”- 84020- Oliveto
| | - R Gentile
- Gentile s.a.s Research Center, Gentile s.a.s Research Center , Gragnano NA, Italy
| | - M Gentile
- Gentile s.a.s Research Center, Gentile s.a.s Research Center , Gragnano NA, Italy
| | - T Gentile
- Gentile s.a.s Research Center, Gentile s.a.s Research Center , Gragnano NA, Italy
| | - M Spinelli
- Department of Chemical Science of Univesrity of Naples Federico II, Department of Chemical Science of Univesrity of Naples Federico II , Napoli, Italy
| | - F Carolina
- Department of Chemical Science of Univesrity of Naples Federico II, Department of Chemical Science of Univesrity of Naples Federico II , Napoli, Italy
| | - T Notari
- Reproductive Unit of Medicine Check Up Polidiagnostic, Reproductive Unit of Medicine Check Up Polidiagnostic , Salerno, Italy
| | - M Piscopo
- Department of Biology University of Naples Federico II, Department of Biology University of Naples Federico II , Napoli, Italy
| | - A Amoresano
- Department of Chemical Science University of Naples Federico II, Department of Chemical Science University of Naples Federico II , Napoli, Italy
| | - S Raimondo
- Gentile s.a.s Research Center, Gentile s.a.s Research Center , Gragnano NA, Italy
| |
Collapse
|
7
|
Gentile M, Raimondo S, Gentile R, Gentile T, Fortunato A, Piscopo M, Crescenzi C, Siani L, Ferrara I, Esposito A, Iaccarino M, Notari T, Sosa Fernandez L, Montano L. O-286 Bisphenol A in blood serum and follicular fluid of women undergoing to cycle of IVF living in areas with different environmental impact. (EcoFoodFertility Project). Hum Reprod 2022. [DOI: 10.1093/humrep/deac106.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Study question
Bisphenol A (BPA) is a constituent of polycarbonate and epoxy resin plastics and is also a by-product of combustion of plastics, resulting harmful for health.
Summary answer
To evaluate the presence of BPA in the blood and Follicular Fluids, in women, subjected to IVF cycles, living in areas with different environmental impact.
What is known already
BPA is used in the production of polycarbonate plastics and epoxy resins. 1,3,5-triphenylbenzene is a tracer for burning plastic and has been related to levels of bisphenol A in the air, so the actual release of bisphenol A to the atmosphere could result from burning the plastic. Bisphenol A belongs to the group of endocrine disruptors.
Little is known about the effects of BPA on human female reproduction. BPA levels appear to be inversely related to the number of oocytes retrieved in IVF cycles, and it also appears to negatively affect the ovulatory peak of estradiol.
Study design, size, duration
In the frame of EcoFoodFertility project a cross sectional study conducted in Campania Region (Southern Italy), between January 2019 and December 2020, 74 women, no smokers, no chronic diseases, not exposed to occupational risk factors. living for at least 5 years in areas with low environmental impact (LEI, 31 women), Alto-Medio Sele in province of Salerno and high environmental impact (HEI, 43 women), so-called “Land of Fires” in province of Naples, were selected.
Participants/materials, setting, methods
Participants have a normal ovarian reserve, average age 32.05 + 3.49, with infertility duration between 26 and 39 months and at the first experience of an IVF cycle. ELISA was used for measuring bisphenol A in blood and Follicular Fluids (FFs), expressed in ng/ mL. 5 mL glass tubes, without additives, not siliconized and kept in a horizontal position were used. FFs were bloodless with a negative albumin test.
Main results and the role of chance
Differents levels of BPA were found in all processed samples.
In the LEI (Low Environmental Impact) group, serum levels vary from a minimum of 3.1 ng/mL to a maximum of 7.7 ng/mL (4.1 ± 1.6) and the Follicular Fluids levels vary from a minimum of 7,1 ng/mL to a maximum of 55.3 ng/mL (13.8 ± 10.9).
In the HEI (High Environmental Impact) group, serum levels vary from a minimum of 69.2 ng/mL to a maximum of 167.8 ng/mL (95.5 ± 24.3) and Follicular Fluids levels vary from a minimum of 4.2 ng/mL to a maximum of 34.3 ng/mL (19.9 ± 9.2).
Statistical processing of the data shows a highly significant variation in serum levels (p < 0.0001) with higher values in the HEI group (95.5 ± 24.3) than in the LEI group (4.1 ± 1.6).
A moderately significant change (p < 0.01) for Follicular Fluids levels, higher in the HEI group (19.9 ± 9.2) than in the LEI group (13.8 ± 10.9).
Furthermore, the data did not show any correspondence between serum and Follicular Fluids for any of the participants tested.
Limitations, reasons for caution
The ELISA method for the determination of BPA seems suitable to us, however, the subject requires further biomonitoring studies, with a larger sample and greater selection of participants, to better understand the effects of BPA and its metabolites in FF and in other districts of the female reproductive system.
Wider implications of the findings
The results indicate that the greater bioaccumulation in women of the HEI group appears consistent with the environmental condition of the area and with the comparative studies already carried out within the EcoFoodFertility project. This is further evidence that pollution in this area can interfere with female fertility and beyond.
Trial registration number
G003
Collapse
Affiliation(s)
- M Gentile
- Laboratory Gentile s.a.s, “Gentile s.a.s.” Research Center , Gragnano, Italy
| | - S Raimondo
- Laboratory Gentile s.a.s, “Gentile s.a.s.” Research Center , Gragnano, Italy
| | - R Gentile
- Laboratory Gentile s.a.s, “Gentile s.a.s.” Research Center , Gragnano, Italy
| | - T Gentile
- Laboratory Gentile s.a.s, “Gentile s.a.s.” Research Center , Gragnano, Italy
| | - A Fortunato
- Pineta Grande Hospital, IVF Laboratory , Caserta, Italy
| | - M Piscopo
- University of Naples Federico II- 80126 Naples- Italy, Department of Biology , Napoli, Italy
| | - C Crescenzi
- Clinic Center “HERA”, IVF Laboratory , Giugliano, Italy
| | - L Siani
- Mediterraneo Center pma”, IVF Laboratory “ , Salerno, Italy
| | - I Ferrara
- Medical Center “Gunè”, IVF Laboratory , Acerra, Italy
| | - A Esposito
- Gynecology and Obstetric Hospital “San Giovanni di Dio”, Coordination Fertility Prevention Unit , Frattamaggiore, Italy
| | - M Iaccarino
- Iaccarino Chemis Center, IVF Laboratory , Napoli, Italy
| | - T Notari
- Check Up-Day Surgery- Polydiagnostic and Research Centre, IVF Laboratory , Salerno, Italy
| | | | - L Montano
- Ospedale San Francesco D’Assisi”-, Andrology Unit and Service of Lifestyle Medicine in UroAndrology- Local Health Authority ASL Salerno- Coordination Unit of the network for Environmental and Reproductive Health Eco-FoodFertility Project “ -, Oliveto Ci
| |
Collapse
|
8
|
Mauro FR, Giannarelli D, Galluzzo C, Visentin A, Frustaci AM, Sportoletti P, Vitale C, Reda G, Gentile M, Levato L, Murru R, Armiento D, Ielo C, Maglione R, Crisanti E, Cipiciani A, Mattiello V, Gianfelici V, Barabino L, Amici R, Coscia M, Tedeschi A, Trentin L, Baroncelli S. P660: SEROLOGIC RESPONSE TO THE SECOND AND THIRD DOSE OF THE SARS-COV-2 VACCINE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A PROSPECTIVE, CENTRALIZED, MULTICENTER STUDY. Hemasphere 2022. [DOI: 10.1097/01.hs9.0000845524.05971.e8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
9
|
Giudice E, Gentile M, Salutari V, Ricci C, Musacchio L, Carbone MV, Ghizzoni V, Camarda F, Tronconi F, Nero C, Ciccarone F, Scambia G, Lorusso D. PARP Inhibitors Resistance: Mechanisms and Perspectives. Cancers (Basel) 2022; 14:cancers14061420. [PMID: 35326571 PMCID: PMC8945953 DOI: 10.3390/cancers14061420] [Citation(s) in RCA: 21] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Revised: 03/07/2022] [Accepted: 03/08/2022] [Indexed: 12/27/2022] Open
Abstract
Simple Summary This review aims to analyze the emerging issue regarding PARP inhibitor’s resistance in tumors and their consequence on disease prognosis and treatment. Besides, we evaluate possible strategies and new therapeutic approaches to overcome PARPis resistance. Abstract PolyADP-ribose polymerase (PARP) inhibitors (PARPis) represent the first clinically approved drugs able to provoke “synthetic lethality” in patients with homologous recombination-deficient (HRD) tumors. Four PARPis have just received approval for the treatment of several types of cancer. Besides, another three additional PARPis underlying the same mechanism of action are currently under investigation. Despite the success of these targeted agents, the increasing use of PARPis in clinical practice for the treatment of different tumors raised the issue of PARPis resistance, and the consequent disease relapse and dismal prognosis for patients. Several mechanisms of resistance have been investigated, and ongoing studies are currently focusing on strategies to address this challenge and overcome PARPis resistance. This review aims to analyze the mechanisms underlying PARPis resistance known today and discuss potential therapeutic strategies to overcome these processes of resistance in the future.
Collapse
Affiliation(s)
- Elena Giudice
- Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168 Rome, Italy; (E.G.); (V.G.); (G.S.)
| | - Marica Gentile
- Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy;
| | - Vanda Salutari
- Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy; (C.R.); (L.M.); (M.V.C.); (C.N.); (F.C.)
- Correspondence: (V.S.); (D.L.); Tel.: +39-06-3015-7337 (D.L.); +39-06-3015-3234 (V.S.)
| | - Caterina Ricci
- Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy; (C.R.); (L.M.); (M.V.C.); (C.N.); (F.C.)
| | - Lucia Musacchio
- Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy; (C.R.); (L.M.); (M.V.C.); (C.N.); (F.C.)
| | - Maria Vittoria Carbone
- Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy; (C.R.); (L.M.); (M.V.C.); (C.N.); (F.C.)
| | - Viola Ghizzoni
- Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168 Rome, Italy; (E.G.); (V.G.); (G.S.)
| | - Floriana Camarda
- Medical Oncology, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168 Rome, Italy;
| | - Francesca Tronconi
- Medical Oncology, Università Politecnica delle Marche, Via Tronto 10/a, 60126 Ancona, Italy;
| | - Camilla Nero
- Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy; (C.R.); (L.M.); (M.V.C.); (C.N.); (F.C.)
| | - Francesca Ciccarone
- Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy; (C.R.); (L.M.); (M.V.C.); (C.N.); (F.C.)
| | - Giovanni Scambia
- Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168 Rome, Italy; (E.G.); (V.G.); (G.S.)
- Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy; (C.R.); (L.M.); (M.V.C.); (C.N.); (F.C.)
| | - Domenica Lorusso
- Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168 Rome, Italy; (E.G.); (V.G.); (G.S.)
- Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy; (C.R.); (L.M.); (M.V.C.); (C.N.); (F.C.)
- Correspondence: (V.S.); (D.L.); Tel.: +39-06-3015-7337 (D.L.); +39-06-3015-3234 (V.S.)
| |
Collapse
|
10
|
Filioglo A, Simaan N, Honig A, Heldner MR, von Rennenberg R, Pezzini A, Padjen V, Rentzos A, Altersberger VL, Baumgartner P, Zini A, Grisendi I, Aladdin S, Gomori JM, Pilgram-Pastor SM, Scheitz JF, Magoni M, Berisavac I, Nordanstig A, Psychogios M, Luft A, Gentile M, Assenza F, Arnold M, Nolte CH, Gamba M, Ercegovac M, Jood K, Engelter ST, Wegener S, Forlivesi S, Zedde M, Gensicke H, Tatlisumak T, Cohen JE, Leker RR. Outcomes after reperfusion therapies in patients with ACA stroke: A multicenter cohort study from the EVATRISP collaboration. J Neurol Sci 2022; 432:120081. [PMID: 34920158 DOI: 10.1016/j.jns.2021.120081] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2021] [Revised: 11/28/2021] [Accepted: 12/01/2021] [Indexed: 11/19/2022]
Abstract
BACKGROUND Patients with stroke secondary to occlusions of the anterior cerebral artery (ACA) often have poor outcomes. The optimal acute therapeutic intervention for these patients remains unknown. METHODS Patients with isolated ACA-stroke were identified from 10 centers participating in the EndoVascular treatment And ThRombolysis in Ischemic Stroke Patients (EVATRISP) prospective registry. Patients treated with endovascular thrombectomy (EVT) were compared to those treated with intravenous thrombolysis (IVT). Odds ratios with 95% confidence intervals (OR; 95%CI) were calculated using multivariate regression analysis. RESULTS Included were 92 patients with ACA-stroke. Of the 92 ACA patients, 55 (60%) were treated with IVT only and 37 (40%) with EVT (±bridging IVT). ACA patients treated with EVT had more often wake-up stroke (24% vs. 6%, p = 0.044) and proximal ACA occlusions (43% vs. 24%, p = 0.047) and tended to have higher stroke severity on admission [NIHSS: 10.0 vs 7.0, p = 0.054). However, odds for favorable outcome, mortality or symptomatic intracranial hemorrhage did not differ significantly between both groups. Exploration of the effect of clot location inside the ACA showed that in patients with A1 or A2/A3 ACA occlusions the chances of favorable outcome were not influenced by treatment allocation to IVT or EVT. DISCUSSION Treatment with either IVT or EVT could be safe with similar effect in patients with ACA-strokes and these effects may be independent of clot location within the occluded ACA.
Collapse
Affiliation(s)
- A Filioglo
- Departments of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - N Simaan
- Departments of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - A Honig
- Departments of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - M R Heldner
- Department of Neurology, University Hospital Bern, Switzerland
| | - R von Rennenberg
- Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin Institute of Health, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
| | - A Pezzini
- Department of Clinical and Experimental Sciences, Neurology Clinic, University of Brescia, Italy
| | - V Padjen
- Neurology Clinic, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - A Rentzos
- Department of Diagnostic and Interventional Neuroradiology, Sahlgrenska University Hospital and Department of Radiology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sweden
| | - V L Altersberger
- Stroke Center and Department of Neurology, University Hospital Basel and University of Basel, Switzerland
| | - P Baumgartner
- University Hospital Zurich and University of Zurich, Switzerland
| | - A Zini
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Department of Neurology and Stroke Center, Maggiore Hospital, Bologna, Italy
| | - I Grisendi
- Neurology Unit, Stroke Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - S Aladdin
- Departments of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - J M Gomori
- Radiology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - S M Pilgram-Pastor
- University Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
| | - J F Scheitz
- Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin Institute of Health, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
| | - M Magoni
- U.O Vascular Neurology, Stroke Unit, ASST Spedali Civili, Brescia, Italy
| | - I Berisavac
- Neurology Clinic, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - A Nordanstig
- Department of Clinical Neurosciences, Institute of Neurosciences and Physiology, Sahlgrenska Academy at University of Gothenburg and Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - M Psychogios
- Department of Neuroradiology, Clinic of Radiology and Nuclear Medicine, University Hospital Basel and University of Basel, Switzerland
| | - A Luft
- University Hospital Zurich and University of Zurich, Switzerland
| | - M Gentile
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Department of Neurology and Stroke Center, Maggiore Hospital, Bologna, Italy
| | - F Assenza
- Neurology Unit, Stroke Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - M Arnold
- Department of Neurology, University Hospital Bern, Switzerland
| | - C H Nolte
- Department of Neurology, Charité-Universitätsmedizin Berlin, Center for Stroke Research, Berlin, Berlin Institute of Health, Berlin, Germany
| | - M Gamba
- University Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
| | - M Ercegovac
- Neurology Clinic, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - K Jood
- Department of Clinical Neurosciences, Institute of Neurosciences and Physiology, Sahlgrenska Academy at University of Gothenburg and Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - S T Engelter
- Stroke Center and Department of Neurology, University Hospital Basel and University of Basel, Switzerland; Neurology and Neurorehabilitation, University Department of Geriatric Medicine FELIX PLATTER, University of Basel, Switzerland
| | - S Wegener
- University Hospital Zurich and University of Zurich, Switzerland
| | - S Forlivesi
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Department of Neurology and Stroke Center, Maggiore Hospital, Bologna, Italy
| | - M Zedde
- Neurology Unit, Stroke Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - H Gensicke
- Stroke Center and Department of Neurology, University Hospital Basel and University of Basel, Switzerland; Neurology and Neurorehabilitation, University Department of Geriatric Medicine FELIX PLATTER, University of Basel, Switzerland
| | - T Tatlisumak
- Department of Clinical Neurosciences, Institute of Neurosciences and Physiology, Sahlgrenska Academy at University of Gothenburg and Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - J E Cohen
- Neurosurgery, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
| | - R R Leker
- Departments of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
| |
Collapse
|
11
|
Zilliacus E, Hathaway J, Cicerchia M, Tommiska J, Ahonen S, Seppälä E, Gall K, Scocchia A, Saarinen I, Rantanen M, Schleit J, Kangas-Kontio T, Gentile M, Salmenperä P, Paananen J, Myllykangas S, Koskenvuo J. Diagnostic Yield of Panel Genetic Testing in a Cohort of >200 Patients With Congenital Heart Disease. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.04.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
12
|
Hathaway J, Zilliacus E, Cicerchia M, Tommiska J, Ahonen S, Seppälä E, Gall K, Scocchia A, Saarinen I, Rantanen M, Schleit J, Kangas-Kontio T, Gentile M, Salmenperä P, Paananen J, Myllykangas S, Koskenvuo J. Genetic Testing for Pulmonary Arterial Hypertension: Diagnostic Yield and Findings From a Cohort of Patients Referred for Targeted Panel Testing. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.04.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
13
|
Gentile M, Iannuzzo G, Simeon V, Mattiello A, Rubba F, Panico C, Panico S, Rubba P. Association between atherogenic index of plasma and carotid intima-media thickness in a cohort of Mediterranean women. Acta Cardiol 2021; 76:987-992. [PMID: 33302810 DOI: 10.1080/00015385.2020.1858537] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
The association between early atherosclerosis (IMT) and Atherogenic index of plasma (AIP), a marker of atherogenicity (log triglycerides/HDL Cholesterol) was evaluated in a population-based cohort study in women, aged 30-69, living in the metropolitan area of Naples, Southern Italy (Progetto ATENA). Serum cholesterol, HDL-cholesterol, LDL-cholesterol, Triglyceride, Insulin, HOMA, Apo B, hs-CPR were measured in 390 menopausal women, as a part of 5.062 participants of the cohort. Women in the second and third tertile of AIP showed an increased common carotid intima-media thickness compared with those in the first tertile: II vs I tertile (O.R. = 2.24, p = 0.007), III vs I tertile (O.R. = 2.29, p = 0.005), adjusted for age and Systolic pressure or II vs I tertile (O.R. = 2.19, p = 0.014), III vs I tertile (O.R. = 2.13, p = 0.026), adjusted for age, Systolic pressure, Body mass index and Apo B. Women in the second and third tertile of AIP compared to those in the first tertile, showed an OR of 2.14 (p = 0.016) and 1.99 (p = 0.033) respectively, of having elevates level of IMT, adjusted for traditional cardiovascular risk factor (age, Systolic Pressure, BMI, LDL Cholesterol, Diabetes diagnosis). This finding shows that in this group of menopausal women increased IMT is associated with elevated AIP independently of age and different cardiovascular risk factors. These results are in line with the hypothesis that AIP may be an useful clinical tools to give additional information in the risk assessment for atherosclerotic disease, in particular in postmenopausal women.
Collapse
Affiliation(s)
- M. Gentile
- Dipartimento di Medicina Clinica e Chirurgia, Università “Federico II” di Napoli, Italy
| | - G. Iannuzzo
- Dipartimento di Medicina Clinica e Chirurgia, Università “Federico II” di Napoli, Italy
| | - V. Simeon
- Unità Statistica Medica, Dipartimento di Salute Mentale e Fisica e Medicina Preventiva, Università degli Studi della Campania ‘Luigi Vanvitelli’, Napoli, Italy
| | - A. Mattiello
- Dipartimento di Medicina Clinica e Chirurgia, Università “Federico II” di Napoli, Italy
| | - F. Rubba
- Dipartimento di Sanità Pubblica, Università degli Studi di Napoli Federico II, Napoli, Italy
| | - C. Panico
- Dipartimento di Medicina Clinica e Chirurgia, Università “Federico II” di Napoli, Italy
| | - S. Panico
- Dipartimento di Medicina Clinica e Chirurgia, Università “Federico II” di Napoli, Italy
| | - P. Rubba
- Dipartimento di Medicina Clinica e Chirurgia, Università “Federico II” di Napoli, Italy
| |
Collapse
|
14
|
Visentin A, Mauro FR, Cibien F, Vitale C, Reda G, Fresa A, Ciolli S, Pietrasanta D, Marchetti M, Murru R, Gentile M, Rigolin GM, Quaglia FM, Scarfò L, Sportoletti P, Pravato S, Romano Gargarella L, Facco M, Piazza F, Marchetti M, Coscia M, Laurenti L, Molica S, Pizzolo G, Foà R, Cuneo A, Trentim L. EFFICACY AND DISCONTINUATION RATE OF IBRUTINIB IN TREATMENT NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH TP53 ABNORMALITIES. A REAL‐LIFE CAMPUS CLL STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.46_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. Visentin
- Hematology and Clinical Immunology Unit, Department of Medicine University of Padova Padova Italy
| | - F. R. Mauro
- Hematology Unit, Department of Translational and Precision Medicine Sapienza" University Rome Italy
| | - F. Cibien
- Hematology Unit Ca’ Foncello Hospital Treviso Italy
| | - C. Vitale
- Department of Molecular Biotechnology and Health Sciences University of Torino and Division of Hematology A.O.U. Città della Salute e della Scienza di Torino Torino Italy
| | - G. Reda
- Hematology Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Milan Italy
| | - A. Fresa
- Hematology Institute Fondazione Policlinico Universitario Agostino Gemelli IRCSS Roma Italy
| | - S. Ciolli
- Hematology Unit, Careggi Hospital University of Florence Florence Italy
| | - D. Pietrasanta
- Division of Hematology A.O. SS Antonio e Biagio and Cesare Arrigo Alessandria Italy
| | - M. Marchetti
- Division of Hematology A.O. SS Antonio e Biagio and Cesare Arrigo Alessandria Italy
| | - R. Murru
- Hematology and Stem Cell Transplantation Unit Ospedale A. Businco, ARNAS “G. Brotzu Cagliari Italy
| | - M. Gentile
- Hematology unit, Department of Hemato‐Oncology Annunziata Hospital Cosenza Italy
| | - G. M. Rigolin
- Hematology section, Department of Medical Sciences Azienda Ospedaliera‐Universitaria, Arcispedale S. Anna, University of Ferrara Ferrara Italy
| | - F. M. Quaglia
- Department of Medicine, Section of Hematology University of Verona & Azienda Ospedaliera Universitaria Integrata Verona Italy
| | - L. Scarfò
- Strategic program on CLL University health and Science “San Raffaele Milan Italy
| | - P. Sportoletti
- Hematology and Clinical Immunology unit University of Perugia Perugia Italy
| | - S. Pravato
- Hematology and Clinical Immunology Unit, Department of Medicine University of Padova Padova Italy
| | - L. Romano Gargarella
- Hematology and Clinical Immunology Unit, Department of Medicine University of Padova Padova Italy
| | - M. Facco
- Hematology and Clinical Immunology Unit, Department of Medicine University of Padova Padova Italy
| | - F. Piazza
- Hematology and Clinical Immunology Unit, Department of Medicine University of Padova Padova Italy
| | - M. Marchetti
- Division of Hematology A.O. SS Antonio e Biagio and Cesare Arrigo Alessandria Italy
| | - M. Coscia
- Department of Molecular Biotechnology and Health Sciences University of Torino and Division of Hematology A.O.U. Città della Salute e della Scienza di Torino Torino Italy
| | - L. Laurenti
- Hematology Institute Fondazione Policlinico Universitario Agostino Gemelli IRCSS Roma Italy
| | - S. Molica
- Department Hematology‐Oncology Azienda Ospedaliera Pugliese‐Ciaccio Catanzaro Italy
| | - G. Pizzolo
- Department of Medicine, Section of Hematology University of Verona & Azienda Ospedaliera Universitaria Integrata Verona Italy
| | - R. Foà
- Hematology Unit, Department of Translational and Precision Medicine Sapienza" University Rome Italy
| | - A. Cuneo
- Hematology section, Department of Medical Sciences Azienda Ospedaliera‐Universitaria, Arcispedale S. Anna, University of Ferrara Ferrara Italy
| | - L. Trentim
- Hematology and Clinical Immunology Unit, Department of Medicine University of Padova Padova Italy
| |
Collapse
|
15
|
Calcaterra I, Gentile M, Iannuzzo G, Tripaldella M, Di Minno A, Forte F, Buonaiuto A, Di Taranto M, Rubba P, Di Minno M. Changes in carotid stiffness in patients with familial hypercholesterolemia treated with evolocumab®: A prospective cohort study. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.866] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
16
|
Buonaiuto A, Gentile M, Calcaterra I, Giacobbe C, Tripaldella M, Forte F, Di Minno M, Iannuzzo G, Fortunato G, Rubba P. Correlation between different LDL-R mutations and response to AB-PCSK9 therapy in a group of patient with genetic diagnosis of familial hypercholesterolemia. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
17
|
Gentile M, Centonza A, Lovero D, Palmirotta R, Porta C, Silvestris F, D'Oronzo S. Application of "omics" sciences to the prediction of bone metastases from breast cancer: State of the art. J Bone Oncol 2020; 26:100337. [PMID: 33240786 PMCID: PMC7672315 DOI: 10.1016/j.jbo.2020.100337] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Revised: 10/23/2020] [Accepted: 10/29/2020] [Indexed: 11/28/2022] Open
Abstract
Breast cancer (BC) is the first cause of cancer-related death in women. Most patients with advanced BC develop bone metastases (BM). Omics technologies have been applied to identify putative BM “predicting” biomarkers. Prospective studies are needed before any clinical application of such biomarkers.
Breast cancer (BC) is the most frequent malignancy and the first cause of cancer-related death in women. The majority of patients with advanced BC develop skeletal metastases which may ultimately lead to serious complications, termed skeletal-related events, that often dramatically impact on quality of life and survival. Therefore, the identification of biomarkers able to stratify BC patient risk to develop bone metastases (BM) is fundamental to define personalized diagnostic and therapeutic strategies, possibly at the earliest stages of the disease. In this regard, the advent of “omics” sciences boosted the investigation of several putative biomarkers of BC osteotropism, including deregulated genes, proteins and microRNAs. The present review revisits the current knowledge on BM development in BC and the most recent studies exploring potential BM-predicting biomarkers, based on the application of omics sciences to the study of primary breast malignancies.
Collapse
Key Words
- ADAMTS1, a disintegrin-like and metalloproteinase with thrombospondin type 1
- ALP, alkaline phosphatase
- BALP (BSAP), bone-specific alkaline phosphatase
- BC, breast cancer
- BM, bone metastases
- BOLCs, breast osteoblast-like cells
- BTM, bone turnover markers
- Biomarkers
- Bone metastases
- Breast cancer
- CAPG, capping-protein
- CCN3, cellular communication network factor 3
- CDH11, cadherin-11
- CNV, copy number variation
- CTGF, connective tissue-derived growth factor
- CTSK, cathepsin K
- CTX, C-telopeptide
- CXCL, C-X-C-ligand
- CXCR, C–X–C motif chemokine receptor
- DEGs, differentially expressed genes
- DOCK4, dedicator of cytokinesis protein 4
- DPD, deoxypyridoline
- DTC, disseminated tumour cells
- EMT, epithelial-to-mesenchymal transition
- ER, estrogen receptor
- ERRα, estrogen-related receptor alpha
- FAK, focal adhesion kinase
- FGF, fibroblast growth factor
- FST, follistatin
- GIPC1, PDZ domain-containing protein member 1
- HR, hazard ratio
- Her, human epidermal growth factor
- ICAM-1, intercellular adhesion molecule 1
- IGF, insulin-like growth factor
- IHC, immunohistochemistry
- IL, interleukin
- LC/MS/MS, liquid chromatography/mass spectrometry/mass spectrometry
- MAF, v-maf avian muscolo aponeurotic fibro-sarcoma oncogene homolog
- MDA-MB, MD Anderson metastatic BC
- MMP1, matrix metalloproteinase-1
- NTX, N-telopeptide
- OPG, osteoprotegerin
- Omics sciences
- Osteotropism
- P1CP, pro-collagen type I C-terminal
- P1NP, pro-collagen type I N-terminal
- PDGF, platelet-derived growth factor
- PRG1, proteoglycan-1
- PTH-rP, parathyroid hormone-related protein
- PYD, pyridoline
- PgR, progesterone receptor
- PlGF, placental growth factor
- RANK, receptor activator of nuclear factor к-B
- RT-PCR, real time-PCR
- SILAC-MS, stable isotope labelling by amino acids in cell culture-mass spectrometry
- SNPs, single nucleotide polymorphisms
- SPP1, osteopontin
- SREs, skeletal-related events
- TCGA, the cancer genome atlas
- TGF-β, transforming growth factor beta
- TNF-α, tumor necrosis factor-α
- TRACP-5b, tartrate resistant acid phosphatase-5b
- VEGF, vascular endothelial growth factor
- ZNF217, zinc-finger protein 217
- miRNAs, microRNAs
- ncRNAs, noncoding RNA
Collapse
Affiliation(s)
- Marica Gentile
- Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Antonella Centonza
- "Casa Sollievo della Sofferenza" Onco-hematologic Department, Medical Oncology Unit, Viale Cappuccini 1, 71013 San Giovanni Rotondo, Italy
| | - Domenica Lovero
- Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Raffaele Palmirotta
- Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Camillo Porta
- Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Franco Silvestris
- Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Stella D'Oronzo
- Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy
| |
Collapse
|
18
|
Calcaterra I, Di Minno A, Gentile M, Tripaldella M, Buonaiuto A, Forte F, Di Taranto M, Giacobbe C, Iannuzzo G, Rubba P, Di Minno M. Changes in markers of subclinical atherosclerosis in patients with familial hypercholesterolemia treated with evolocumab: a prospective cohort study. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
PCSK-9-i demonstrated efficacy in cholesterol reduction and prevention of cardiovascular events.
Purpose
Changes in lipid-profile, oxidative stress and subclinical atherosclerosis markers in patients with familial hypercholesterolemia (FH) during 12 weeks of treatment with PCSK-9-i.
Methods
Patients with FH starting a treatment with Evolocumab® were included. TC, LDL-C, Lp(a), small dense LDL (assessed byLDL score), 11-dehydro-thromboxane (11-TXB2), 8-iso-prostaglandin-2alpha (8-iso-PGF2α),FMD, RHI and carotid stiffness were evaluated at baseline and after 12weeks of treatment.
Results
25 subjects were enrolled (52% males, mean age 51.5 years). At the 12-week, the median reduction was 38% for TC, 52% for LDL-C, 7% for Lp(a) and 46% for LDL score; 11-TXB2 and 8-iso-PGF2α were reduced of 18% and 17%, respectively. FMD changed from4.78%±2.27 to10.6%±5.89 (p<0.001), with RHI changing from 2.37±1.23 to 3.76±1.36 (p<0.001). Carotid stiffness changed from 8.8 (IQR: 7.0–10.4)m/sec to 6.6 m/sec (IQR: 5.4–7.5), p<0.001). At a multivariate analysis, changes in LDL score predicted changes in FMD (β=−0.846, p=0.015) in carotid stiffness (β=0.429, p=0.041), and in 8-iso-PGF2α (β=0.778, p=0.012).
Conclusions
Small dense LDL reduction is related to changes in oxidative stress and in subclinical atherosclerosis markers in FH patients treated with Evolocumab®.
Changes in endothelial function
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
| | - A Di Minno
- Federico II University Hospital, Naples, Italy
| | - M Gentile
- Federico II University Hospital, Naples, Italy
| | | | - A Buonaiuto
- Federico II University Hospital, Naples, Italy
| | - F Forte
- Federico II University Hospital, Naples, Italy
| | | | - C Giacobbe
- Federico II University Hospital, Naples, Italy
| | - G Iannuzzo
- Federico II University Hospital, Naples, Italy
| | - P.O.F Rubba
- Federico II University Hospital, Naples, Italy
| | | |
Collapse
|
19
|
Buonaiuto A, Gentile M, Calcaterra I, Giacobbe C, Tripaldella M, Forte F, Iannuzzo G, Di Minno M, Fortunato G, Rubba P. Correlation between different LDL-R mutations and response to ab-PCSK9 therapy in a group of patient with genetic diagnosis of Familial Hypercholesterolemia. Preliminary report. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3332] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Familial hypercholesterolemia (FH) is an autosomal dominant disease that leads to premature cardiovascular disease (CAD). The availability of ab-PCSK9 has changed the approach to therapy.
Purpose
To evaluate the relationship between different types of mutations in LDLR gene and response to ab-PCSK9.
Methods
73 FH patients, 33 women and 40 men (53.9±13. yrs), in primary prevention (N=46) and secondary prevention (N=27), were recruited. This sample included patients with mutations in LDLR gene: heterozygotes for missense mutations (N=31), for null mutations (N=31), compound heterozygotes or homozygotes (N=11). At baseline, the whole sample had a maximally tolerated lipid lowering therapy (MT-LLT) without ab-PCSK9; 16 patients had MT-LLTs intolerance. After 160 days with ab-PCSK9 therapy we evaluated the achievement of a goal (LDL-C<70 mg/dL in primary prevention without Diabetes Mellitus, LDL-C<55 mg/dL).
Results
After 160 days of therapy with ab-PCSK9 (45 patients on Alirocumab, 28 patients on Evolocumab) and MT-LLT, 29/73 patients (39.7%) of the whole sample achieve the goal of LDL-C. Of them 14/29 (48.2%) were in primary prevention, 15/29 (51.7%) in secondary prevention, no difference in achievement of the goal. We then evaluated the percent of patients achieving the goal of LDL-C:
15/31 (48.3%) patients with missense mutation and 14/31 (45.1%) patients with null mutation, no significant difference among groups;
0/11 compound heterozygotes or homozygotes;
3/16 (18.7%) MT-LLTs intolerance.
The other main cardiovascular risk factors did not influence of the achievement the goal of LDL cholesterol.
Conclusions
Lack of correlation between type of mutation in heterozygous FH patients and ab-PCSK9 therapy response; response was significantly poorest in patients with compound heterozygosis or homozygosis mutation as compared to heterozygotes; the intolerance to MT-LLT was significant in the achievement of the goal of LDL-C.
Different between guideline 2016 vs 2019
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- A Buonaiuto
- ASL Napoli 1 Centre, Dipartimento di Medicina Clinica e Chirurgia, Università “Federico II” di Napoli, Napoli, Italy, Napoli, Italy
| | - M Gentile
- ASL Napoli 1 Centre, Dipartimento di Medicina Clinica e Chirurgia, Università “Federico II” di Napoli, Napoli, Italy, Napoli, Italy
| | - I.L Calcaterra
- ASL Napoli 1 Centre, Dipartimento di Medicina Clinica e Chirurgia, Università “Federico II” di Napoli, Napoli, Italy, Napoli, Italy
| | - C Giacobbe
- ASL Napoli 1 Centre, 2Dipartimento di Medicina molecolare e Biotecnologie mediche, Università “Federico II” di Napoli, Na, Napoli, Italy
| | - M Tripaldella
- ASL Napoli 1 Centre, Dipartimento di Medicina Clinica e Chirurgia, Università “Federico II” di Napoli, Napoli, Italy, Napoli, Italy
| | - F Forte
- ASL Napoli 1 Centre, Dipartimento di Medicina Clinica e Chirurgia, Università “Federico II” di Napoli, Napoli, Italy, Napoli, Italy
| | - G Iannuzzo
- ASL Napoli 1 Centre, Dipartimento di Medicina Clinica e Chirurgia, Università “Federico II” di Napoli, Napoli, Italy, Napoli, Italy
| | - M.N.D Di Minno
- ASL Napoli 1 Centre, Dipartimento di Medicina Clinica e Chirurgia, Università “Federico II” di Napoli, Napoli, Italy, Napoli, Italy
| | - G Fortunato
- ASL Napoli 1 Centre, 2Dipartimento di Medicina molecolare e Biotecnologie mediche, Università “Federico II” di Napoli, Na, Napoli, Italy
| | - P.O.F Rubba
- ASL Napoli 1 Centre, Dipartimento di Medicina Clinica e Chirurgia, Università “Federico II” di Napoli, Napoli, Italy, Napoli, Italy
| |
Collapse
|
20
|
Lavorgna M, Angelillo S, Gentile M, Nugnes R, Orlo E, Russo C, Isidori M. Early genotoxic effects from exposure to environmental pollutants young people from South Italy. Eur J Public Health 2020. [DOI: 10.1093/eurpub/ckaa166.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Children and young people are particularly sensitive to the environmental pollution which is closely related to degenerative diseases. Several studies show that a genotoxic damage during young age can increase the risk of chronic diseases in adulthood. The young people are more vulnerable than adults to the environmental pollutants because they spend more time outdoors, they have immaturity of some organs and of the mechanisms involved in the cellular repair. In the present study, the early biological effects of exposure to a particularly polluted area of Southern Italy were evaluated in 200 children (6-10 year-old) and 100 young people (18-25 year-old). This area, worldwide known as Sarno basin, is characterized by strong anthropization, many agro-food processing industries, massive use of fertilizers and pesticides in agricultural practices and a strong river pollution. The comet assay was chosen because it reflects cumulative exposure to a variety of environmental factors and it was performed on salivary leukocytes in the children selected for the survey, while in the young people the DNA damage was evaluated in human peripheral blood lymphocytes. As in previous studies were not find significant differences between salivary leukocytes and blood lymphocytes we preferred the sampling of saliva for the children to avoid bloody practices. Furthermore, before cell sampling the children's parents were interviewed using an ad hoc questionnaire designed to gather additional information about exposure sources. A questionnaire was administered also to the young people to have more information on their lifestyle and some characteristic of the area of exposure (vehicular traffic and so on). The results showed a clear damage from exposure in the children differently from young people.
Key messages
Comet assay was performed in vitro on lymphocytes of 200 children (6-10 year-old) and 100 young people (18-25 year-old) exposed to a particularly polluted area of Southern Italy. An evident DNA damage was observed in lymphocytes coming from children; no genetic material alterations were observed in young people.
Collapse
Affiliation(s)
- M Lavorgna
- DiSTABiF, Università della Campania, Caserta, Italy
| | - S Angelillo
- DiSTABiF, Università della Campania, Caserta, Italy
| | - M Gentile
- DiSTABiF, Università della Campania, Caserta, Italy
| | - R Nugnes
- DiSTABiF, Università della Campania, Caserta, Italy
| | - E Orlo
- DiSTABiF, Università della Campania, Caserta, Italy
| | - C Russo
- DiSTABiF, Università della Campania, Caserta, Italy
| | - M Isidori
- DiSTABiF, Università della Campania, Caserta, Italy
| |
Collapse
|
21
|
Palmieri S, Rocco S, Vitagliano O, Catalano L, Cerchione C, Vincelli ID, Scopelliti A, Gentile M, Farina G, Barone M, Gagliardi A, Esposito D, Arcamone M, Amico V, Fontana R, Sementa A, Sica A, Svanera G, Pane F, Ferrara F. KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients. Ann Hematol 2020; 99:2903-2909. [PMID: 32583088 DOI: 10.1007/s00277-020-04158-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2019] [Accepted: 06/18/2020] [Indexed: 10/24/2022]
Abstract
From April 2016, carfilzomib, in combination with lenalidomide and dexamethasone (KRD), became available for use in the daily practice in Italy for patients with relapsed or refractory multiple myeloma (RRMM). We performed a retrospective survey at 14 different institutions from Southern Italy in order to evaluate patient characteristics and treatment results from an unselected series of patients treated accordingly so far. One hundred and twenty-three consecutive patients were included, with a median of 2 previous lines of therapy (range 1-9) and a median age of 63 years (range 39-82). At the time of analysis, median number of courses administered is 11 (range 1-34), and all patients are evaluable for response. Overall response rate including complete remission, very good partial remission, and partial remission is 85%. After a median follow-up of 27 months, median overall and progression-free survival are 33 and 23 months, respectively. Sixty-three patients are alive and between them, 45 (37%) are in continuous remission. Sixty patients have died (49%), mainly from progressive disease. There were 6 treatment-related deaths (5% of the whole patient population). Overall, hematological and non-hematological toxicity were manageable, mostly on outpatient basis. Arterial hypertension has been observed in 43 cases (35%) but did not lead to treatment interruption. Our data demonstrate that in real life, KRD is highly effective and well tolerated in the majority of patients with RRMM.
Collapse
Affiliation(s)
| | - S Rocco
- Hematology, "Cardarelli" Hospital, Naples, Italy
| | - O Vitagliano
- Hematology, "Cardarelli" Hospital, Naples, Italy
| | - L Catalano
- Hematology, AUOP "Federico II", Naples, Italy
| | - C Cerchione
- Hematology, AUOP "Federico II", Naples, Italy
| | - I D Vincelli
- Hematology Unit, "Bianchi-Melacrino-Morelli" Hospital, Reggio Calabria, Italy
| | - A Scopelliti
- Hematology Unit, "Bianchi-Melacrino-Morelli" Hospital, Reggio Calabria, Italy
| | - M Gentile
- Onco-Hematology, Hematology Unit, AO of Cosenza, Italy
| | - G Farina
- Onco-Hematology, "S. Anna e S. Sebastiano" Hospital, Caserta, Italy
| | - M Barone
- Onco-Hematology, "Tortora" Hospital, Pagani, SA, Italy
| | - A Gagliardi
- Hematology, "Santa Maria di Loreto Nuovo" Hospital, Naples, Italy
| | - D Esposito
- Hematology, "San Giuseppe Moscati" Hospital, Aversa, CE, Italy
| | - M Arcamone
- Hematology/Oncology and SCT Unit, National Cancer Institute, Fondazione "Pascale", Naples, Italy
| | - V Amico
- Hematology, "Rummo" Hospital, Benevento, Italy
| | - R Fontana
- Hematology, AOU "Ruggi d'Aragona", Salerno, Italy
| | - A Sementa
- Hematology and SCT Unit, "San Giuseppe Moscati" Hospital, Avellino, Italy
| | - A Sica
- Onco-Hematology, AOU "Vanvitelli", Naples, Italy
| | - G Svanera
- Hematology, "San Giuliano" Hospital, Giugliano in Campania, Naples, Italy
| | - F Pane
- Hematology, AUOP "Federico II", Naples, Italy
| | - F Ferrara
- Hematology, "Cardarelli" Hospital, Naples, Italy
| |
Collapse
|
22
|
Venturini E, Iannuzzo G, D’Andrea A, Pacileo M, Tarantini L, Canale M, Gentile M, Vitale G, Sarullo F, Vastarella R, Di Lorenzo A, Testa C, Parlato A, Vigorito C, Giallauria F. Oncology and Cardiac Rehabilitation: An Underrated Relationship. J Clin Med 2020; 9:E1810. [PMID: 32532011 PMCID: PMC7356735 DOI: 10.3390/jcm9061810] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2020] [Revised: 06/04/2020] [Accepted: 06/08/2020] [Indexed: 02/06/2023] Open
Abstract
Cancer and cardiovascular diseases are globally the leading causes of mortality and morbidity. These conditions are closely related, beyond that of sharing many risk factors. The term bidirectional relationship indicates that cardiovascular diseases increase the likelihood of getting cancer and vice versa. The biological and biochemical pathways underlying this close relationship will be analyzed. In this new overlapping scenario, physical activity and exercise are proven protective behaviors against both cardiovascular diseases and cancer. Many observational studies link an increase in physical activity to a reduction in either the development or progression of cancer, as well as to a reduction in risk in cardiovascular diseases, a non-negligible cause of death for long-term cancer survivors. Exercise is an effective tool for improving cardio-respiratory fitness, quality of life, psychological wellbeing, reducing fatigue, anxiety and depression. Finally, it can counteract the toxic effects of cancer therapy. The protection obtained from physical activity and exercise will be discussed in the various stages of the cancer continuum, from diagnosis, to adjuvant therapy, and from the metastatic phase to long-term effects. Particular attention will be paid to the shelter against chemotherapy, radiotherapy, cardiovascular risk factors or new onset cardiovascular diseases. Cardio-Oncology Rehabilitation is an exercise-based multi-component intervention, starting from the model of Cardiac Rehabilitation, with few modifications, to improve care and the prognosis of a patient's cancer. The network of professionals dedicated to Cardiac Rehabilitation is a ready-to-use resource, for implementing Cardio-Oncology Rehabilitation.
Collapse
Affiliation(s)
- E. Venturini
- Cardiac Rehabilitation Unit, Azienda USL Toscana Nord-Ovest, Cecina Civil Hospital, 57023 LI Cecina, Italy
| | - G. Iannuzzo
- Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, Italy; (G.I.); (M.G.)
| | - A. D’Andrea
- Unit of Cardiology and Intensive Care, “Umberto I” Hospital, Viale San Francesco, Nocera Inferiore, 84014 SA, Italy; (A.D.); (M.P.)
| | - M. Pacileo
- Unit of Cardiology and Intensive Care, “Umberto I” Hospital, Viale San Francesco, Nocera Inferiore, 84014 SA, Italy; (A.D.); (M.P.)
| | - L. Tarantini
- Division of Cardiology, Ospedale San Martino ULSS1 Dolomiti, 32100 Belluno, Italy;
| | - M.L. Canale
- Department of Cardiology, Azienda USL Toscana Nord-Ovest, Ospedale Versilia, Lido di Camaiore, 55041 LU, Italy;
| | - M. Gentile
- Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, Italy; (G.I.); (M.G.)
| | - G. Vitale
- Cardiovascular Rehabilitation Unit, Buccheri La Ferla Fatebenefratelli Hospital, 90123 Palermo, Italy; (G.V.); (F.M.S.)
| | - F.M. Sarullo
- Cardiovascular Rehabilitation Unit, Buccheri La Ferla Fatebenefratelli Hospital, 90123 Palermo, Italy; (G.V.); (F.M.S.)
| | - R. Vastarella
- UOSD Scompenso Cardiaco e Cardiologia Riabilitativa, AORN Ospedale dei Colli-Monaldi, 80131 Naples, Italy;
| | - A. Di Lorenzo
- Department of Translational Medical Sciences, Federico II University of Naples, 80131 Naples, Italy; (A.D.L.); (C.T.); (A.P.); (C.V.); (F.G.)
| | - C. Testa
- Department of Translational Medical Sciences, Federico II University of Naples, 80131 Naples, Italy; (A.D.L.); (C.T.); (A.P.); (C.V.); (F.G.)
| | - A. Parlato
- Department of Translational Medical Sciences, Federico II University of Naples, 80131 Naples, Italy; (A.D.L.); (C.T.); (A.P.); (C.V.); (F.G.)
| | - C. Vigorito
- Department of Translational Medical Sciences, Federico II University of Naples, 80131 Naples, Italy; (A.D.L.); (C.T.); (A.P.); (C.V.); (F.G.)
| | - F. Giallauria
- Department of Translational Medical Sciences, Federico II University of Naples, 80131 Naples, Italy; (A.D.L.); (C.T.); (A.P.); (C.V.); (F.G.)
| |
Collapse
|
23
|
Gentile M, Zinna M, Zanella C, Costanza A, Dalfior D, Sina S, Greco F, Fiorica F, Colombari R, Catapano P, Bonetti A, Remo A. Uterine PEComa with aggressive behavior: A review with an additional case of spontaneous vaginal expulsion. Pathol Res Pract 2020; 216:152991. [PMID: 32527449 DOI: 10.1016/j.prp.2020.152991] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/24/2020] [Accepted: 04/22/2020] [Indexed: 11/28/2022]
Abstract
Perivascular epithelioid cell tumor (PEComa) is a rare mesenchymal tumor originating from perivascular epitheloid cells showing melanocytic and smooth muscle differentiation. The uterus represents the second most common site of origin. A 49 years woman presented to our Hospital for a vaginal spontaneous expulsion of a mass suggestive for malignant mesenchymal tumor. The patient underwent total hysterectomy and bilateral salpingo-oophorectomy and the histopathological report was compliant with a PEComa with aggressive behavior. Medical Literature databases about PEComa were searched. The current literature identified near 90 cases of uterine PEComas and they are categorized as uncertain malignant potential or with aggressive behavior. Primary surgical excision represents the gold-standard treatment. Recently targeted therapy with mTOR inhibitors has been introduced with an important beneficial. In this paper we review the Literature about the uPEComa with aggressive behavior reporting the first case of spontaneous vaginal expulsion.
Collapse
Affiliation(s)
- M Gentile
- Obstetrics and Gynecology Unit, Surgical Department, ULSS 9 "Scaligera", Verona, Italy
| | - M Zinna
- Obstetrics and Gynecology Unit, Surgical Department, ULSS 9 "Scaligera", Verona, Italy
| | - C Zanella
- Oncology Unit, Oncology Department, ULSS9 "Scaligera", Verona, Italy
| | - A Costanza
- Obstetrics and Gynecology Unit, Surgical Department, ULSS 9 "Scaligera", Verona, Italy
| | - D Dalfior
- Pathology Unit, Service Department, ULSS9 "Scaligera", Verona, Italy
| | - S Sina
- Oncology Unit, Oncology Department, ULSS9 "Scaligera", Verona, Italy
| | - F Greco
- Oncology Unit, Oncology Department, ULSS9 "Scaligera", Verona, Italy
| | - F Fiorica
- Radiotherapy Unit, Oncology Department, ULSS9 "Scaligera", Verona, Italy
| | - R Colombari
- Pathology Unit, Service Department, ULSS9 "Scaligera", Verona, Italy
| | - P Catapano
- Obstetrics and Gynecology Unit, Surgical Department, ULSS 9 "Scaligera", Verona, Italy
| | - A Bonetti
- Oncology Unit, Oncology Department, ULSS9 "Scaligera", Verona, Italy
| | - A Remo
- Pathology Unit, Service Department, ULSS9 "Scaligera", Verona, Italy.
| |
Collapse
|
24
|
Abstract
We obtain the linear instability and nonlinear stability thresholds for a problem of thermal convection in a rotating bidispersive porous medium with a single temperature. We show that the linear instability threshold is the same as the nonlinear stability one. This means that the linear theory is capturing completely the physics of the onset of thermal convection.
Collapse
Affiliation(s)
- F. Capone
- Dipartimento di Matematica e Appl. ‘R.Caccioppoli’, Università degli Studi di Napoli Federico II, Via Cintia, Monte S. Angelo, I-80126 Napoli, Italy
| | - R. De Luca
- Dipartimento di Matematica e Appl. ‘R.Caccioppoli’, Università degli Studi di Napoli Federico II, Via Cintia, Monte S. Angelo, I-80126 Napoli, Italy
| | - M. Gentile
- Dipartimento di Matematica e Appl. ‘R.Caccioppoli’, Università degli Studi di Napoli Federico II, Via Cintia, Monte S. Angelo, I-80126 Napoli, Italy
| |
Collapse
|
25
|
Abstract
Retroperitoneal sarcomas are extremely rare malignant tumors. The most common type of sarcomas arising in the retroperitoneum are liposarcomas, occurring mostly in the sixth and seventh decades of life. The only potentially curative approach to liposarcomas is the complete surgical resection of the tumor with negative microscopic margins. However, retroperitoneal liposarcomas exhibit a propensity for local recurrence and distant metastasis despite the negative surgical margins, thus requiring additional therapy. Eribulin demonstrated a benefit in terms of overall survival in patients with advanced or metastatic liposarcoma. We report two cases of patients, both submitted to concomitant right nephrectomy, who experienced a long-lasting control of recurrent retroperitoneal liposarcoma before being submitted to eribulin-based therapeutic regimens (23 and 24 treatment cycles completed, respectively).
Collapse
Affiliation(s)
- Nastassja Tober
- Azienda Ospedaliero-Universitaria Policlinico Sant'Orsola-Malpighi di Bologna, Bologna, Italy
| | - Marica Gentile
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Bari, Italy
| | - Giuseppe Iodice
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Bari, Italy
| |
Collapse
|
26
|
Raponi S, Del Giudice I, Marinelli M, Wang J, Cafforio L, Ilari C, Piciocchi A, Messina M, Bonina S, Tavolaro S, Bordyuh M, Mariglia P, Peragine N, Mauro FR, Chiaretti S, Molica S, Gentile M, Visentin A, Trentin L, Rigolin GM, Cuneo A, Diop F, Rossi D, Gaidano G, Guarini A, Rabadan R, Foà R. Genetic landscape of ultra-stable chronic lymphocytic leukemia patients. Ann Oncol 2019; 29:966-972. [PMID: 29365086 DOI: 10.1093/annonc/mdy021] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background Chronic lymphocytic leukemia (CLL) has a heterogeneous clinical course. Beside patients requiring immediate treatment, others show an initial indolent phase followed by progression and others do not progress for decades. The latter two subgroups usually display mutated IGHV genes and a favorable FISH profile. Patients and methods Patients with absence of disease progression for over 10 years (10-34) from diagnosis were defined as ultra-stable CLL (US-CLL). Forty US-CLL underwent extensive characterization including whole exome sequencing (WES), ultra-deep sequencing and copy number aberration (CNA) analysis to define their unexplored genetic landscape. Microarray analysis, comparing US-CLL with non-US-CLL with similar immunogenetic features (mutated IGHV/favorable FISH), was also carried out to recognize US-CLL at diagnosis. Results WES was carried out in 20 US-CLL and 84 non-silent somatic mutations in 78 genes were found. When re-tested in a validation cohort of 20 further US-CLL, no recurrent lesion was identified. No clonal mutations of NOTCH1, BIRC3, SF3B1 and TP53 were found, including ATM and other potential progression driving mutations. CNA analysis identified 31 lesions, none with known poor prognostic impact. No novel recurrent lesion was identified: most cases showed no lesions (38%) or an isolated del(13q) (31%). The expression of 6 genes, selected from a gene expression profile analysis by microarray and quantified by droplet digital PCR on a cohort of 79 CLL (58 US-CLL and 21 non-US-CLL), allowed to build a decision-tree capable of recognizing at diagnosis US-CLL patients. Conclusions The genetic landscape of US-CLL is characterized by the absence of known unfavorable driver mutations/CNA and of novel recurrent genetic lesions. Among CLL patients with favorable immunogenetics, a decision-tree based on the expression of 6 genes may identify at diagnosis patients who are likely to maintain an indolent disease for decades.
Collapse
Affiliation(s)
- S Raponi
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - I Del Giudice
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - M Marinelli
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - J Wang
- Division of Life Science and Department of Chemical and Biological Engineering, Hong Kong University of Science and Technology, Hong Kong
| | - L Cafforio
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - C Ilari
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - A Piciocchi
- GIMEMA Data Centre, GIMEMA Foundation, Rome, Italy
| | - M Messina
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Bonina
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Tavolaro
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - M Bordyuh
- Department of Systems Biology, Columbia University, New York, USA; Department of, Biomedical Informatics, Columbia University, New York, USA
| | - P Mariglia
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - N Peragine
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - F R Mauro
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Chiaretti
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Molica
- Department of Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy
| | - M Gentile
- Hematology Uni, Department of Hemato-Oncology, Ospedale Annunziata, Cosenza, Italy
| | - A Visentin
- Hematology Sectio, Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
| | - L Trentin
- Hematology Sectio, Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
| | - G M Rigolin
- Hematology Sectio, Azienda Ospedaliero Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - A Cuneo
- Hematology Sectio, Azienda Ospedaliero Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - F Diop
- Division of Hematolog, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - D Rossi
- Department of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Institute of Oncology Research, Bellinzona, Switzerland
| | - G Gaidano
- Division of Hematolog, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - A Guarini
- Department of Molecular Medicine, Sapienza University, Rome, Italy
| | - R Rabadan
- Department of Systems Biology, Columbia University, New York, USA; Department of, Biomedical Informatics, Columbia University, New York, USA
| | - R Foà
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
| |
Collapse
|
27
|
Sita T, Hassanzadeh C, Savoor R, Samson P, Bradley J, Gentile M, Roach M, Mohindra N, Waqar S, Robinson C, Kruser T. OA03.03 Multi-Institutional Study of Pneumonitis After Treatment with Durvalumab and Chemoradiotherapy for Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.034] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
28
|
Rubba F, Gentile M, Scamardo MS, Iannuzzo G, Panico C, Pacilio M, D’Onofrio G, Panico S, Rubba P, Triassi M. Prognostic and Predictive biomarkers in a Mediterranean cohort (Review from Atena Project). Eur J Public Health 2019. [DOI: 10.1093/eurpub/ckz187.137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Atena project involved 5,062 women aged 30 to 69 years living in the area of Naples. The purpose of this study is to investigate the causes of those chronic diseases that have a major impact on the female population. As a part of the design (scheduled in 2002-2004). After 10 years, in 228 women, some biochemical measurements were performed.
Methods
This systematic review and meta-analysis biomarkers were evaluated in studies nested into the Atena cohort. Studies were searched using MEDLINE/PubMed. The search was performed by entering individually or in combination: Atena, Mediterranean woman, biomarkers. The preferred reporting of systematic reviews and meta-analysis (PRISMA) guidelines were used for the review. Studies selected for this review are conducted in the Atena project Cohort and reported the study of biomarkers. Disagreements on data extractions between the two investigators were solved by consensus. The extracted data were entered and analyzed using REVMAN software. The original articles were described using forest plot and table. Heterogeneity was computed by Cochran’s Q test.
Results
The search strategy retrieved 13 potential articles, 11 were screened as full text articles and 6 were included in the pooled estimates. Among the articles included, biomarkers chosen as predictors were Lipids, Hcrp, as prognostic where predictive of IMT; and cycle length and LPa as predictive of an augmented LDL cholesterol mean. According to the comparability of data presented, for the first comparison we selected 3 of the 5 studies that assed IMT, for the second we selected 2 of the three studies that analyzed for LDL mean. Results were shown into forrest plots. The pooled estimates verified the potential of biomarkers as predictor of IMT, the significance seemed lower for prediction of LDL cholesterol.
Conclusions
Both results, consistent with the multifactor profile of the CV risk, identify the impact of secondary prevention according to biochemical profiles.
Key messages
Biomarkers studied in nested cohort stufies have predictive potential. pooled estimates may identify the impact of secondary prevention according to biochemical profiles.
Collapse
Affiliation(s)
- F Rubba
- AOU Federico II, Naples, Italy
| | | | | | | | | | | | | | | | - P Rubba
- AOU Federico II, Naples, Italy
| | | |
Collapse
|
29
|
Sabatino A, Regolisti G, Mario FD, Parmigiani A, Vari M, Farina M, Gentile M, Ciuni A, Palumbo A, Fiaccadori E. QUADRICEPS FEMORIS MUSCLE THICKNESS BY ULTRASOUND IN ACUTE KIDNEY INJURY: VALIDATION BY COMPUTERIZED TOMOGRAPHY. Nutrition 2019. [DOI: 10.1016/j.nut.2019.08.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
30
|
Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter M, Herling C, De Paoli L, Delgado J, Gentile M, Doubek M, Mauro F, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Moia R, Gerber B, Zucca E, Ghielmini M, Cavalli F, Stüssi G, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foà R, Pospisilova S, Morabito F, Wierda W, Montserrat E, Gaidano G, Hallek M, Rossi D. INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (IPS-A). Hematol Oncol 2019. [DOI: 10.1002/hon.51_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- A. Condoluci
- Experimental Hematology; Institute of Oncology Research; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - L. Terzi di Bergamo
- Experimental Hematology; Institute of Oncology Research; Bellinzona Switzerland
| | - P. Langerbeins
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - M. Hoechstetter
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - C. Herling
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - L. De Paoli
- Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - J. Delgado
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - M. Gentile
- Hematology; Azienda Ospedaliera (AO) of Cosenza; Cosenza Italy
| | - M. Doubek
- Hematology and Oncology; University Hospital of Brno; Brno Czech Republic
| | - F.R. Mauro
- Hematology; Sapienza University; Rome Italy
| | - G. Chiodin
- Hematology; Southampton University; Southampton United Kingdom
| | - M. Mattsson
- Immunology; Genetics and Pathology, Uppsala University; Uppsala Sweden
| | - J. Bahlo
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - G. Cutrona
- Hematology; IRCCS Ospedale Policlinico San Martino; Genoa Italy
| | - J. Kotaskova
- Hematology and Oncology; University Hospital of Brno; Brno Czech Republic
| | - C. Deambrogi
- Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - R. Moia
- Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - B. Gerber
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - E. Zucca
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - M. Ghielmini
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - F. Cavalli
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - G. Stüssi
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - A. Neri
- Hematology; University of Milan; Milan Italy
| | | | - R. Rosenquist
- Immunology; Genetics and Pathology, Uppsala University; Uppsala Sweden
| | - F. Forconi
- Hematology; Southampton University; Southampton United Kingdom
| | - R. Foà
- Hematology; Sapienza University; Rome Italy
| | - S. Pospisilova
- Hematology and Oncology; University Hospital of Brno; Brno Czech Republic
| | - F. Morabito
- Hematology; Augusta Victoria Hospital; Jerusalem Israel
| | - W.G. Wierda
- MD Anderson Cancer Center; University of Texas; Houston United States
| | - E. Montserrat
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - G. Gaidano
- Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - M. Hallek
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - D. Rossi
- Experimental Hematology; Institute of Oncology Research; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| |
Collapse
|
31
|
Chanzy E, Gentile M, Nahon M, Paty AC, Stibbe O, Tourtier JP, Petrovic T, Goix L, Adnet F, Lapostolle F. COP21 – Organisation et bilan d’une médicalisation sous haute tension. Rev Epidemiol Sante Publique 2019; 67:201-204. [DOI: 10.1016/j.respe.2019.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2016] [Revised: 02/11/2019] [Accepted: 02/15/2019] [Indexed: 10/27/2022] Open
|
32
|
Prescott A, Strauss J, Donnelly E, Gentile M, Patel R, Lipps D, Oza S. EP-1288 Dosimetric Comparison of Protons and Photons in Musculoskeletal Sparing During Breast Irradiation. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31708-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
33
|
Reda G, Cassin R, Gentile M, Mauro FR, Giannarelli D, Fattizzo B, Barbieri M, Silvestris I, Fabris S, Morabito F, Neri A, Barcellini W, Cortelezzi A. IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia. Leukemia 2019; 33:1519-1522. [PMID: 30635629 DOI: 10.1038/s41375-018-0344-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2018] [Revised: 11/27/2018] [Accepted: 11/30/2018] [Indexed: 01/21/2023]
Affiliation(s)
- G Reda
- Hematology Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
| | - R Cassin
- Hematology Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - M Gentile
- Hematology Unit, Department of Onco-hematology, A.O. Cosenza, Cosenza, Italy
| | - F R Mauro
- Hematology, Department of Cellular Biotechnologies and Hematology, 'Sapienza' University, Rome, Italy
| | - D Giannarelli
- Biostatistic Unit, Regina Elena National Institute for Cancer Treatment and Research, Rome, Italy
| | - B Fattizzo
- Hematology Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - M Barbieri
- Hematology Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - I Silvestris
- Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
| | - S Fabris
- Hematology Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - F Morabito
- Hemato-oncology Department, Augusta Victoria Hospital, Mount of Olives, Jerusalem, Israel.,Biotechnology Research Unit, Aprigliano, Cosenza, Italy
| | - A Neri
- Hematology Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.,Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
| | - W Barcellini
- Hematology Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - A Cortelezzi
- Hematology Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.,Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
| |
Collapse
|
34
|
Gridelli C, Iacobelli S, Martino T, Natoli C, Ferrante G, Gentile M, Irtelli L, Beltrami V, Rossi A, Bianco AR. Neoadjuvant Chemotherapy with Cisplatin, Epirubicin and VP-16 for Stage IIIA-IIIB Non-Small-Cell Lung Cancer: A Pilot Study. Tumori 2018; 78:377-9. [PMID: 1338403 DOI: 10.1177/030089169207800606] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Twenty patients with stage IIIA-IIIB non-small-cell lung cancer were treated with cisplatin, epirubicin and VP-16 (PEV) neoadjuvant chemotherapy (CDDP, 70 mg/m2, i.v., d 1; EDX, 60 mg/m2, i.v., d 1; VP-16, 100 mg/m2, i.v., d 1-2-3; every 3 weeks). A partial response was obtained In 11 cases (55%), stable disease in 3 cases (15%), and progressive disease in 6 cases (30%). After chemotherapy, 8 (40%) patients, all achieving a partial response, were elegible for surgery: 5 (25%) had a complete resection (4 IIIA and 1 IIIB) and 3 (15%) an incomplete resection. The treatment was well tolerated. These data show that PEV is an active regimen for neoadjuvant chemotherapy in NSCLC and recommend this therapeutic approach for stage IIIA patients.
Collapse
Affiliation(s)
- C Gridelli
- Cattedra di Oncologia Medica, II Facoltà di Medicina, Università di Napoli, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Bianco AR, Stefani S, Gridelli C, Gentile M, Contegiacomo A, Giampaglia F, Lauria R, Conte A, Ferrante G. Intensive Alternating Combination Chemotherapy and High Dose Chest Radiotherapy in Small Cell Lung Cancer. Tumori 2018; 77:437-41. [PMID: 1664155 DOI: 10.1177/030089169107700513] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Sixty-nine patients, 32 with limited and 37 with extensive small cell lung cancer (SCLC), were admitted to the present study. Patients with limited disease underwent alternating combination chemotherapy consisting of CAV (cyclophosphamide, adriamycin, vincristine) and PE (cisplatin and etoposide) regimens and concurrent high dose thoracic radiotherapy (6,000 cGy); prophylactic brain irradiation (3,000 cGy) was administered to complete responders. Patients with extensive disease received the same alternating chemotherapy but not radiotherapy. In the 25 evaluable patients with limited disease we obtained an objective response (OR) in 80% with a complete response (CR) in 54% and partial response (PR) in 24%, stable disease (SD) in 4% and progressive disease (PD) in 16%. Median duration of response was 9.5 months for CR and 8.5 months for PR. Median survival was 14 months for all patients with 12% long-term survivors. Toxicity was acceptable. In the 32 evaluable patients with extensive disease we observed 65.6% OR with 18.7% CR and 46.8% PR, 9.3% minimal response and 25% PD. Median duration of response was 7 months for CR and 8 months for PR. Median survival was 10 months for all patients. The treatment was well tolerated. Our study did not show a therapeutic advantage for alternating combination chemotherapy in SCLC and failed to show the use of high dose chest radiotherapy in combined modality for limited disease.
Collapse
Affiliation(s)
- A R Bianco
- Cattedra di Oncologia Medica, 2a Facoltà di Medicina, Università di Napoli, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Abstract
A bidispersive porous material is one which has usual pores but additionally contains a system of micro pores. We consider a fluid-saturated bidispersive porous medium in the vertical layer
x
∈(−1/2,1/2) with gravity in the −
z
(downward) direction. The walls of the layer are maintained at different constant temperatures. A suitable Rayleigh number is defined and we derive a global stability threshold below which no instability may arise. We additionally show that the porous layer is stable for all Rayleigh numbers provided the initial temperature gradient is bounded in a precise sense.
Collapse
Affiliation(s)
- M. Gentile
- Dipartimento di Matematica e Appl. ‘R.Caccioppoli’, Università degli Studi di Napoli Federico II, Via Cintia, Monte S. Angelo 80126, Napoli, Italy
| | - B. Straughan
- Department of Mathematical Sciences, Durham University, Durham DH1 3LE, UK
| |
Collapse
|
37
|
Frigeni M, Visco C, Besson C, Rattotti S, Fontaine H, Goldaniga M, Visentini M, Torres H, Peveling-Oberhag J, Rossotti R, Zaja F, Rigacci L, Merli M, Dorival C, Alric L, Piazza F, Gentile M, Ferrari A, Pirisi M, Tedeschi A, Defrancesco I, Ferretti V, Bruno R, Hermine O, Arcaini L. INTERFERON-FREE ANTIVIRAL TREATMENT IN B-CELL LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH CHRONIC HEPATITIS-C VIRUS INFECTION. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Frigeni
- Department of Molecular Medicine; University of Pavia; Pavia Italy
| | - C. Visco
- Department of Cell Therapy and Hematology; San Bortolo Hospital; Vicenza Italy
| | - C. Besson
- Université Paris Sud, INSERM; Assistance Publique-Hôpitaux de Paris Centre Hospitalier Universitaire Bicêtre; Le Kremlin-Bicêtre France
| | - S. Rattotti
- Department of Hematology Oncology; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo; Pavia Italy
| | - H. Fontaine
- Paris 5 Descartes University; INSERM U1213 and Unité Mixte de Service 20; Institut Pasteur, Department of Hepatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris; Paris France
| | - M. Goldaniga
- Department of Hematology, Fondazione Ospedale Maggiore Policlinico; Mangiagalli e Regina Elena; Milan Italy
| | - M. Visentini
- Division of Clinical Immunology; Sapienza University of Rome, Fondazione Roma; Rome Italy
| | - H.A. Torres
- Department of Infectious Diseases, Infection Control, and Employee Health; The University of Texas MD Anderson Cancer Center; Houston Texas USA
| | - J. Peveling-Oberhag
- Department of Internal Medicine 1; Goethe-University Hospital; Frankfurt Germany
| | - R. Rossotti
- Department of Infectious Diseases; Ospedale Niguarda Ca’ Granda; Milan Italy
| | - F. Zaja
- Hematology Unit, Centro Trapianti e Terapie Cellulari Carlo Melzi, DISM, Azienda Sanitaria Universitaria Integrata; Udine Italy
| | - L. Rigacci
- Department of Hematology; Azienda Ospedaliero-Universitaria Careggi; Florence Italy
| | - M. Merli
- Division of Hematology, Ospedale di Circolo e Fondazione Macchi; University of Insubria; Varese Italy
| | - C. Dorival
- Sorbonne Universités, Pierre and Marie Curie University (University of Paris 06), INSERM; Institut Pierre Louis d'épidémiologie et de Santé Publique (Unité mixte de recherche S1136); Paris France
| | - L. Alric
- Toulouse 3 University, Unité mixte de recherche 152 Institut de Recherche pour le Développement; Department of Internal Medicine and Digestive Diseases, Hôpital Purpan; Toulouse France
| | - F. Piazza
- Hematology and Clinical Immunology Unit, Department of Medicine; University of Padua; Padua Italy
| | - M. Gentile
- Hematology Unit; Azienda Ospedaliera di Cosenza; Cosenza Italy
| | - A. Ferrari
- Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico; Reggio Emilia Italy
| | - M. Pirisi
- Department of Translational Medicine; Università degli Studi del Piemonte Orientale "A. Avogadro"; Novara Italy
| | - A. Tedeschi
- Department of Hematology, Niguarda Cancer Center, Ospedale Niguarda Ca’ Granda; Milan Italy
| | - I. Defrancesco
- Department of Molecular Medicine; University of Pavia; Pavia Italy
| | - V.V. Ferretti
- Department of Molecular Medicine; University of Pavia; Pavia Italy
| | - R. Bruno
- Division of Infectious and Tropical Diseases, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo; Pavia Italy
| | - O. Hermine
- Paris 5 Descartes University; AP-HP, Department of Adult Hematology and Imagine Institute, Hôpital Necker; Paris France
| | - L. Arcaini
- Department of Hematology Oncology; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo; Pavia Italy
| |
Collapse
|
38
|
Barisione G, Fabbi M, Cutrona G, De Cecco L, Zupo S, Leitinger B, Gentile M, Manzoni M, Neri A, Morabito F, Ferrarini M, Ferrini S. Heterogeneous expression of the collagen receptor DDR1 in chronic lymphocytic leukaemia and correlation with progression. Blood Cancer J 2017; 6:e513. [PMID: 28060374 PMCID: PMC5301030 DOI: 10.1038/bcj.2016.121] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Affiliation(s)
- G Barisione
- IRCCS AOU San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
| | - M Fabbi
- IRCCS AOU San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
| | - G Cutrona
- IRCCS AOU San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
| | - L De Cecco
- Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
| | - S Zupo
- IRCCS AOU San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
| | - B Leitinger
- Section of Molecular Medicine, National Heart and Lung Institute, Imperial College London, UK
| | - M Gentile
- Hematology Unit Azienda Ospedaliera of Cosenza, Cosenza, Italy
| | - M Manzoni
- Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.,Hematology Unit, Fondazione Cà Granda IRCCS Ospedale Maggiore Policlinico, Milan, Italy
| | - A Neri
- Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.,Hematology Unit, Fondazione Cà Granda IRCCS Ospedale Maggiore Policlinico, Milan, Italy
| | - F Morabito
- Hematology Unit Azienda Ospedaliera of Cosenza, Cosenza, Italy.,Biotechnology Research Unit, Aprigliano, ASP of Cosenza, Cosenza, Italy
| | - M Ferrarini
- IRCCS AOU San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
| | - S Ferrini
- IRCCS AOU San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
| |
Collapse
|
39
|
Cutrona G, Matis S, Colombo M, Massucco C, Baio G, Valdora F, Emionite L, Fabris S, Recchia AG, Gentile M, Neumaier CE, Reverberi D, Massara R, Boccardo S, Basso L, Salvi S, Rosa F, Cilli M, Zupo S, Truini M, Tassone P, Calabrese M, Negrini M, Neri A, Morabito F, Fais F, Ferrarini M. Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy. Leukemia 2017; 31:1894-1904. [DOI: 10.1038/leu.2016.394] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2016] [Revised: 11/27/2016] [Accepted: 12/06/2016] [Indexed: 12/23/2022]
|
40
|
Ronchetti D, Manzoni M, Agnelli L, Vinci C, Fabris S, Cutrona G, Matis S, Colombo M, Galletti S, Taiana E, Recchia AG, Bossio S, Gentile M, Musolino C, Di Raimondo F, Grilli A, Bicciato S, Cortelezzi A, Tassone P, Morabito F, Ferrarini M, Neri A. lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome. Blood Cancer J 2016; 6:e468. [PMID: 27611921 PMCID: PMC5056969 DOI: 10.1038/bcj.2016.77] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2016] [Accepted: 08/01/2016] [Indexed: 12/29/2022] Open
Abstract
Long non-coding RNAs (lncRNAs) represent a novel class of functional RNA molecules with an important emerging role in cancer. To elucidate their potential pathogenetic role in chronic lymphocytic leukemia (CLL), a biologically and clinically heterogeneous neoplasia, we investigated lncRNAs expression in a prospective series of 217 early-stage Binet A CLL patients and 26 different subpopulations of normal B-cells, through a custom annotation pipeline of microarray data. Our study identified a 24-lncRNA-signature specifically deregulated in CLL compared with the normal B-cell counterpart. Importantly, this classifier was validated on an independent data set of CLL samples. Belonging to the lncRNA signature characterizing distinct molecular CLL subgroups, we identified lncRNAs recurrently associated with adverse prognostic markers, such as unmutated IGHV status, CD38 expression, 11q and 17p deletions, and NOTCH1 mutations. In addition, correlation analyses predicted a putative lncRNAs interplay with genes and miRNAs expression. Finally, we generated a 2-lncRNA independent risk model, based on lnc-IRF2-3 and lnc-KIAA1755-4 expression, able to distinguish three different prognostic groups in our series of early-stage patients. Overall, our study provides an important resource for future studies on the functions of lncRNAs in CLL, and contributes to the discovery of novel molecular markers with clinical relevance associated with the disease.
Collapse
Affiliation(s)
- D Ronchetti
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - M Manzoni
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - L Agnelli
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - C Vinci
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - S Fabris
- Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy
| | - G Cutrona
- Molecular Pathology Unit, IRCCS-A.O.U. San Martino-IST, Genoa, Italy
| | - S Matis
- Molecular Pathology Unit, IRCCS-A.O.U. San Martino-IST, Genoa, Italy
| | - M Colombo
- Molecular Pathology Unit, IRCCS-A.O.U. San Martino-IST, Genoa, Italy
| | - S Galletti
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
| | - E Taiana
- Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy
| | - A G Recchia
- Hematology Unit, Department of Onco-Hematology, A.O. of Cosenza, Cosenza, Italy.,Biotechnology Research Unit, Aprigliano, A.O./ASP of Cosenza, Cosenza, Italy
| | - S Bossio
- Hematology Unit, Department of Onco-Hematology, A.O. of Cosenza, Cosenza, Italy.,Biotechnology Research Unit, Aprigliano, A.O./ASP of Cosenza, Cosenza, Italy
| | - M Gentile
- Hematology Unit, Department of Onco-Hematology, A.O. of Cosenza, Cosenza, Italy
| | - C Musolino
- School and Division of Hematology, University Hospital 'G. Martino', Messina, Italy
| | - F Di Raimondo
- Department of Biomedical Sciences, Division of Haematology, University of Catania and Ferrarotto Hospital, Catania, Italy
| | - A Grilli
- Center for Genome Research Dept. of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy
| | - S Bicciato
- Center for Genome Research Dept. of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy
| | - A Cortelezzi
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.,Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy
| | - P Tassone
- Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy
| | - F Morabito
- Hematology Unit, Department of Onco-Hematology, A.O. of Cosenza, Cosenza, Italy.,Biotechnology Research Unit, Aprigliano, A.O./ASP of Cosenza, Cosenza, Italy
| | - M Ferrarini
- Scientific Direction, IRCCS-A.O.U. San Martino-IST, Genoa, Italy
| | - A Neri
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.,Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy
| |
Collapse
|
41
|
Volpe P, Contro E, Fanelli T, Muto B, Pilu G, Gentile M. Appearance of fetal posterior fossa at 11-14 weeks in fetuses with Dandy-Walker malformation or chromosomal anomalies. Ultrasound Obstet Gynecol 2016; 47:720-725. [PMID: 25914043 DOI: 10.1002/uog.14883] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/02/2015] [Revised: 04/08/2015] [Accepted: 04/16/2015] [Indexed: 06/04/2023]
Abstract
OBJECTIVE To describe the sonographic appearance of fetal posterior fossa anatomy at 11-14 weeks of pregnancy and to assess the outcome of fetuses with increased intracranial translucency (IT) and/or brainstem-to-occipital bone (BSOB) diameter. METHODS Reference ranges for brainstem (BS), IT and cisterna magna (CM) measurements, BSOB diameter and the BS : BSOB ratio were obtained from the first-trimester ultrasound examination of 233 fetuses with normal postnatal outcome (control group). The intraobserver and interobserver variability of measurements were investigated using 73 stored ultrasound images. In addition, a study group of 17 fetuses with increased IT and/or BSOB diameter was selected to assess outcome. RESULTS No significant intraobserver or interobserver variability was found for any measurement in the control group. In the study group, IT was increased in all cases and BSOB diameter was above the 95(th) centile of the calculated normal range in all but two (88%) cases. In 13/17 study cases, only two of the three posterior brain spaces were recognized on ultrasound. These 13 fetuses had a larger BSOB diameter than did the four cases that showed all three posterior brain spaces, and had severe associated anomalies including Dandy-Walker malformation (DWM) and/or chromosomal anomalies. CONCLUSIONS Visualization of the fetal posterior fossa anatomy at 11-14 weeks' gestation is feasible. Increased fluid in the posterior brain at 11-14 weeks, particularly in the case of non-visibility of the septation that divides the future fourth ventricle from the CM, is an important risk factor for cystic posterior fossa malformations, in particular DWM, and/or chromosomal aberrations. Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd.
Collapse
Affiliation(s)
- P Volpe
- Fetal Medicine Unit, Di Venere and Sarcone Hospitals, ASL BA, Bari, Italy
| | - E Contro
- Department of Obstetrics and Gynecology, University of Bologna, Bologna, Italy
| | - T Fanelli
- Fetal Medicine Unit, Di Venere and Sarcone Hospitals, ASL BA, Bari, Italy
| | - B Muto
- Fetal Medicine Unit, Di Venere and Sarcone Hospitals, ASL BA, Bari, Italy
| | - G Pilu
- Department of Obstetrics and Gynecology, University of Bologna, Bologna, Italy
| | - M Gentile
- Medical Genetics Unit, Di Venere Hospital, ASL BA, Bari, Italy
| |
Collapse
|
42
|
Martino M, Tripepi G, Messina G, Vincelli ID, Console G, Recchia AG, Gentile M, Molica S, Morabito F. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy. Bone Marrow Transplant 2016; 51:1197-203. [DOI: 10.1038/bmt.2016.94] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2015] [Revised: 01/27/2016] [Accepted: 02/26/2016] [Indexed: 11/09/2022]
|
43
|
Pierangeli A, Cannella F, Scagnolari C, Gentile M, Sciandra I, Antonelli G, Ciolfi C, Russo C, Palaia G, Romeo U, Polimeni A. Frequent detection of high human papillomavirus DNA loads in oral potentially malignant disorders. Clin Microbiol Infect 2016; 22:95.e9-95.e15. [DOI: 10.1016/j.cmi.2015.09.011] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2015] [Revised: 07/23/2015] [Accepted: 09/10/2015] [Indexed: 12/13/2022]
|
44
|
Azzini C, Gentile M, De Vito A, Traina L, Sette E, Fainardi E, Mascoli F, Casetta I. Very Early Carotid Endarterectomy After Intravenous Thrombolysis. Eur J Vasc Endovasc Surg 2015; 51:482-6. [PMID: 26712132 DOI: 10.1016/j.ejvs.2015.11.006] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2015] [Accepted: 11/11/2015] [Indexed: 10/22/2022]
Abstract
OBJECTIVE/BACKGROUND The timing of carotid endarterectomy (CEA) after thrombolysis is still a matter of debate. The aim of this study was to analyse a cohort of patients undergoing urgent endarterectomy after intravenous thrombolysis for acute ischaemic stroke. METHODS This was an observational study. Prospective databases were reviewed and matched to identify patients who underwent CEA early after intravenous thrombolysis (2009-14). The focus was carotid surgery performed within 12 hours of stroke onset in patients with a high grade (≥70%) symptomatic carotid stenosis, associated with vulnerable plaques or stroke in evolution, and evidence of a significant salvageable ischaemic penumbra on perfusion computed tomography scan. Demographic and clinical information, as well as data on relevant outcomes were extracted. RESULTS Thirty four consecutive stroke patients who underwent CEA within 2 weeks of thrombolysis for acute ischaemic stroke and ipsilateral high grade carotid stenosis were identified. In 11 patients the surgical procedure was performed within 12 hours of the onset of symptoms. All patients showed a clinical improvement after combined treatment. The 3 month outcome was favourable (modified Rankin Scale ≤ 2) in 10 patients. No haemorrhagic complications were registered. There was neither peri-operative stroke nor stroke within 3 months of surgery. One patient died from acute myocardial infarction 3 days after intervention. CONCLUSION This experience suggests that very early CEA after thrombolysis, aimed at removing the source of potential embolisation and restoring blood flow, may be safe and can lead to a favourable outcome.
Collapse
Affiliation(s)
- C Azzini
- Unità Operativa di Neurologia, Azienda Ospedaliera-Universitaria, Ferrara, Via Aldo Moro 8, 44124 Ferrara-Cona, Italy
| | - M Gentile
- Unità Operativa di Clinica Neurologica, Dipartimento di Scienze Biomediche e Chirurgico-Specialistiche, Università di Ferrara, Via Aldo Moro 8, 44124 Ferrara-Cona, Italy
| | - A De Vito
- Unità Operativa di Neurologia, Azienda Ospedaliera-Universitaria, Ferrara, Via Aldo Moro 8, 44124 Ferrara-Cona, Italy
| | - L Traina
- Unità Operativa di Chirurgia Vascolare, Azienda Ospedaliera-Universitaria, Ferrara, Via Aldo Moro 8, 44124 Ferrara-Cona, Italy
| | - E Sette
- Unità Operativa di Neurologia, Azienda Ospedaliera-Universitaria, Ferrara, Via Aldo Moro 8, 44124 Ferrara-Cona, Italy
| | - E Fainardi
- Unità Operativa di Neuroradiologia, Azienda Ospedaliera-Universitaria, Ferrara, Via Aldo Moro 8, 44124 Ferrara-Cona, Italy
| | - F Mascoli
- Unità Operativa di Chirurgia Vascolare, Azienda Ospedaliera-Universitaria, Ferrara, Via Aldo Moro 8, 44124 Ferrara-Cona, Italy
| | - I Casetta
- Unità Operativa di Clinica Neurologica, Dipartimento di Scienze Biomediche e Chirurgico-Specialistiche, Università di Ferrara, Via Aldo Moro 8, 44124 Ferrara-Cona, Italy.
| |
Collapse
|
45
|
Gentile M, Shanafelt TD, Cutrona G, Molica S, Tripepi G, Alvarez I, Mauro FR, Di Renzo N, Di Raimondo F, Vincelli I, Todoerti K, Matis S, Musolino C, Fabris S, Vigna E, Levato L, Zupo S, Angrilli F, Consoli U, Festini G, Longo G, Cortelezzi A, Arcari A, Federico M, Mannina D, Recchia AG, Neri A, Kay NE, Ferrarini M, Morabito F. A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients. Leukemia 2015; 30:1440-3. [PMID: 26648537 DOI: 10.1038/leu.2015.333] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- M Gentile
- Department of Onco-hematology, Hematology Unit, A.O. of Cosenza, Cosenza, Italy
| | - T D Shanafelt
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - G Cutrona
- Dipartimento di diagnostica della patologia e delle cure ad alta complessità tecnologica, SS Molecular Diagnostics IRCCS S. Martino-IST, Genova, Italy
| | - S Molica
- Department of Oncology and Haematology, Pugliese-Ciaccio Hospital, Catanzaro, Italy
| | - G Tripepi
- Consiglio Nazionale delle Ricerche, Istituto di Fisiologia Clinica, Reggio Calabria, Italy
| | - I Alvarez
- Division of Haematology, Dipartimento Oncologico e Tecnologie Avanzate, Arcispedale S. Maria Nuova/IRCCS, Reggio Emilia, Italy
| | - F R Mauro
- Divisione di Ematologia, Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza, Roma, Italy
| | - N Di Renzo
- Hematology Unit, Ospedale Vito Fazzi, Lecce, Italy
| | - F Di Raimondo
- Division of Haematology, Department of Biomedical Sciences, University of Catania and Ferrarotto Hospital, Catania, Italy
| | - I Vincelli
- Hematology Unit, Dipartimento di Onco-Ematologia, A.O. of Reggio Calabria, Reggio Calabria, Italy
| | - K Todoerti
- Laboratory of Preclinical and Translational Research, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Dipartimento Onco-Ematologico, Potenza, Italy
| | - S Matis
- Direzione Scientifica IRCCS, San Martino IST, Genova, Italy
| | - C Musolino
- Division of Haematology, Dipartimento di Medicina Interna,University of Messina, Messina, Italy
| | - S Fabris
- Department of Clinical Sciences and Community Health, University of Milano and Hematology CTMO, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
| | - E Vigna
- Department of Onco-hematology, Hematology Unit, A.O. of Cosenza, Cosenza, Italy
| | - L Levato
- Department of Oncology and Haematology, Pugliese-Ciaccio Hospital, Catanzaro, Italy
| | - S Zupo
- Dipartimento di diagnostica della patologia e delle cure ad alta complessità tecnologica, SS Molecular Diagnostics IRCCS S. Martino-IST, Genova, Italy
| | - F Angrilli
- Department of Hematology, Ospedale Santo Spirito, Pescara, Italy
| | - U Consoli
- U.O.S. di Emato-Oncologia, Ospedale Garibaldi-Nesima, Catania, Italy
| | - G Festini
- Dipartimento ad Attività Integrata Oncologia, Centro di Riferimento Ematologico-Seconda Medicina, Azienda Ospedaliero-Universitaria, Ospedali Riuniti, Trieste, Italy
| | - G Longo
- Dipartimento di Oncologia, Unità di Ematologia, Ospedale San Vincenzo, Taormina, Italy
| | - A Cortelezzi
- Department of Clinical Sciences and Community Health, University of Milano and Hematology CTMO, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
| | - A Arcari
- Dipartimento di Oncologia ed Ematologia, Hematology Unit, Department of Onco-Hematology, Guglielmo da Saliceto Hospital, Piacenza, Italy
| | - M Federico
- Department of Onco-hematology, Università di Modena Centro Oncologico Modenese, Policlinico Modena, Italy
| | - D Mannina
- Divisione di Ematologia, Ospedale Papardo, Messina, Italy
| | - A G Recchia
- Biotechnology Research Unit, Azienda Sanitaria Provinciale di Cosenza, Aprigliano, Cosenza, Italy
| | - A Neri
- Department of Clinical Sciences and Community Health, University of Milano and Hematology CTMO, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
| | - N E Kay
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - M Ferrarini
- Direzione Scientifica IRCCS, San Martino IST, Genova, Italy
| | - F Morabito
- Department of Onco-hematology, Hematology Unit, A.O. of Cosenza, Cosenza, Italy.,Biotechnology Research Unit, Azienda Sanitaria Provinciale di Cosenza, Aprigliano, Cosenza, Italy
| |
Collapse
|
46
|
Picchetto L, Capitelli M, Dell'Acqua M, Bigliardi G, Fontana M, Barbi F, Romagnoli E, Gentile M, Pentore R, Vandelli L, Baldini T, Rosafio F, Barozzi G, Cioni G, Nichelli P, Zini A. Telestroke modena project: Hub and spoke comparison. J Neurol Sci 2015. [DOI: 10.1016/j.jns.2015.08.324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
47
|
Vannuccini E, Paccagnini E, Cantele F, Gentile M, Dini D, Fino F, Mencarelli C, Lupetti P. Ultrastructural studies of Intraflagellar Transport trains in Chlamydomonas reinhardtii suggest a revision of the current model for IFT trafficking in the flagellar compartment. Cilia 2015. [PMCID: PMC4519114 DOI: 10.1186/2046-2530-4-s1-o16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
48
|
Fainardi E, Bortolotti D, Bolzani S, Castellazzi M, Tamborino C, Roversi G, Baldi E, Caniatti ML, Casetta I, Gentili V, Granieri E, Rizzo R, Granieri E, Castellazzi M, Casetta I, Tola MR, Fainardi E, Dallocchio F, Bellini T, Rizzo R, Rotola A, Di Luca D, Seraceni S, Contini C, Sabbioni S, Negrini M, Tognon M, Antonelli T, Groppo E, Gentile M, Baldi E, Caniatti ML, Ceruti S, Manfrinato MR, Trentini A, Bortolotti D, Miotto E, Ferracin M, Mazzoni E, Pietrobon S, Masini I, Rotondo JC, Martini F, Baruzzi A, Roberto D’Alessandro R, Michelucci R, Salvi F, Stecchi S, Scandellari C, Terzano G, Granella F, Nichelli P, Sola P, Ferraro D, Vitetta F, Simone AM, Bedin R, Marcello N, Motti L, Montepietra S, Guidetti D, Immovilli P, Montanari E, Pesci I, Guareschi A, Greco G, Santangelo M, Mauro AM, Malagù S, Rasi F, Spadoni M, Galeotti M, Fiorani L, Neri W, Ravasio A, Pasquinelli M, Gutman S, Monaldini C. Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis. Mult Scler 2015; 22:245-9. [DOI: 10.1177/1352458515590647] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2015] [Accepted: 05/13/2015] [Indexed: 11/15/2022]
Abstract
Background: The relevance of human leukocyte antigen (HLA)-G in dimeric form in multiple sclerosis (MS) is still unknown. Objective: To investigate the contribution of cerebrospinal fluid (CSF) HLA-G dimers in MS pathogenesis. Methods: CSF amounts of 78-kDa HLA-G dimers were measured by western blot analysis in 80 MS relapsing–remitting MS (RRMS) patients and in 81 inflammatory and 70 non-inflammatory controls. Results: CSF amounts of 78kDa HLA-G dimers were more frequent in RRMS than in inflammatory ( p<0.01) and non-inflammatory controls ( p<0.001) and in magnetic resonance imaging (MRI) inactive than in MRI active RRMS ( p<0.00001). Conclusion: Our findings suggest that HLA-G dimers may be implicated in termination of inflammatory response occurring in MS.
Collapse
Affiliation(s)
- Enrico Fainardi
- Department of Neurosciences and Rehabilitation, Neuroradilogy Unit, Azienda Ospedaliero-Universitaria, Arcispedale S. Anna, Ferrara, Italy
| | - Daria Bortolotti
- Department of Medical Sciences, Section of Microbiology and Medical Genetics, University of Ferrara, Ferrara, Italy
| | - Silvia Bolzani
- Department of Medical Sciences, Section of Microbiology and Medical Genetics, University of Ferrara, Ferrara, Italy
| | - Massimiliano Castellazzi
- Department of Biomedical and Specialist Surgical Sciences, Section of Neurology, University of Ferrara, Ferrara, Italy
| | - Carmine Tamborino
- Department of Biomedical and Specialist Surgical Sciences, Section of Neurology, University of Ferrara, Ferrara, Italy
| | - Gloria Roversi
- Department of Biomedical and Specialist Surgical Sciences, Section of Neurology, University of Ferrara, Ferrara, Italy
| | - Eleonora Baldi
- Department of Neurosciences and Rehabilitation, Neurology Unit, Azienda Ospedaliero-Universitaria, Arcispedale S. Anna, Ferrara, Italy
| | - Maria Luisa Caniatti
- Department of Neurosciences and Rehabilitation, Neurology Unit, Azienda Ospedaliero-Universitaria, Arcispedale S. Anna, Ferrara, Italy
| | - Ilaria Casetta
- Department of Biomedical and Specialist Surgical Sciences, Section of Neurology, University of Ferrara, Ferrara, Italy
| | - Valentina Gentili
- Department of Medical Sciences, Section of Microbiology and Medical Genetics, University of Ferrara, Ferrara, Italy
| | - Enrico Granieri
- Department of Biomedical and Specialist Surgical Sciences, Section of Neurology, University of Ferrara, Ferrara, Italy
| | - Roberta Rizzo
- Department of Medical Sciences, Section of Microbiology and Medical Genetics, University of Ferrara, Ferrara, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Mauro FR, Chauvie S, Paoloni F, Biggi A, Cimino G, Rago A, Gentile M, Morabito F, Coscia M, Bellò M, Sacchetti GM, Rossi D, Laurenti L, Autore F, Campanelli M, Trastulli F, Nicolai E, Riminucci M, Gaidano G, Guarini A, Gallamini A, Foà R. Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. Leukemia 2015; 29:1360-5. [DOI: 10.1038/leu.2015.21] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2014] [Revised: 10/25/2014] [Accepted: 12/10/2014] [Indexed: 11/09/2022]
|
50
|
Zinna M, Gentile M, Torcia F, Bianchi P, Cozza G, Marziani R, Milazzo GN, Catalano A, Di Properzio M, Manzara F, Schimberni M, Caserta D, Frega A. Diagnostic accuracy of sonohysterography vs hysteroscopy in benign uterine endocavitary findings. Eur Rev Med Pharmacol Sci 2015; 19:365-371. [PMID: 25720704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
OBJECTIVE To compare diagnostic accuracy of sonohysterography vs hysteroscopy in patients with benign uterine endocavitary findings. PATIENTS AND METHODS This retrospective study evaluated 202 patients submitted to sonohysterography after transvaginal ultrasound examination suspicious for uterine endocavitary findings. Cytological sample was taken and analyzed from the fluid used to distend the uterine cavity. Of 202 patients enrolled for this study, 86 patients underwent gynaecological surgery, of whom 77 were treated with operative hysteroscopy and 9 with other gynaecological surgical techniques. Statistical analysis was performed to evaluate diagnostic agreement between sonohysterography vs hysteroscopy and cytology vs histology. RESULTS Diagnostic concordance between sonohysterography and hysteroscopy was significant (k value 0.87). The correlation between cytological and histological findings had a moderate level of concordance (k value 0.49). CONCLUSIONS Sonohysterography provides a diagnostic accuracy as well as hysteroscopy, therefore, it could be considered an alternative procedure in the diagnosis of benign uterine endocavitary findings.
Collapse
Affiliation(s)
- M Zinna
- Department of Gynecological, Obstetric and Urological Sciences, "Sapienza" University of Rome, Sant'Andrea Hospital, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|